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1. Introduction 
For the flavonoid quercetin multiple beneficial health effects were postulated, e.g. regarding 
the risk of fatal or non-fatal coronary artery diseases, the risk of lung cancer, the incidence of 
asthma and the impairment of pulmonary functions in chronic obstructive pulmonary disease, 
to name just a few (reviewed in 1-3). Until today, quercetin has been investigated intensively 
in vivo and in vitro, in order to understand its mechanism of action. The most popular 
mechanism for quercetin postulated is its antioxidative activity. Quercetin may reduce 
electrons from reactive oxygen species (4, 5) and is able to chelate free metal ions like Cu
2+
 
and Fe
3+
, which either act directly pro-oxidative or catalyze pro-oxidative processes (6-8). 
There is also evidence that quercetin derived antioxidative effects are attributed to modulating 
gene expression at the level of intracellular signaling pathways and transcription factors. One 
single transcription factor is able to regulate the gene expression of numerous enzymes. 
Hence, by modulating gene expression, quercetin influences biotransformation and other 
metabolic processes as well. Biotransformation of xenobiotics, like drugs or mycotoxins, is 
crucial for the exposition of tissues to those potentially harming substances. During 
biotransformation xenobiotics and endogenous lipophilic compounds are usually detoxified 
by increasing their hydrophilicity and their elimination via bile and urine. 
The mycotoxin ochratoxin A (OTA) is produced by some species of the storage moulds 
Penicillium and Aspergillus as a secondary metabolite. Contaminated food and feed are 
mainly of vegetal origin and are found worldwide. OTA is primarily toxic to the kidney 
(nephrotoxic). For OTA, the popular mode of action postulated is a pro-oxidative effect. It has 
been assumed, that OTA generates reactive oxygen species (ROS) on the one side and down-
regulates gene expression of antioxidative enzymes on the other side, resulting in oxidative 
stress.  
Subject of this work was to examine whether dietary applicated quercetin influences OTA 
toxicity in growing male F344 rats. According to our hypothesis, OTA derived oxidative stress 
might be diminished due to quercetin, when OTA and quercetin are co-administered. We also 
investigated, if quercetin influenced OTA toxicokinetics, because it was recently shown, that 
quercetin and OTA might compete for particular common efflux transporter at the level of the 
intestinal brush border membrane (9). 
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2. The mycotoxin ochratoxin A  
Mycotoxins are produced by moulds as secondary metabolites on contaminated food and 
feed. Moulds are being distinguished in field fungi and storage fungi. Ochratoxins derive 
from some species of the storage fungi Penicillium and Aspergillus during inappropriate 
storage conditions. Naturally occurring ochratoxins are OTA, ochratoxin B and ochratoxin C. 
Chemically, OTA contains a derivative of isocoumarine (7-carboxy-5-chloro-8-hydroxy-3,4-
dihydro-3R-methylisocoumarin), also called ochratoxin α (OTα), linked to the acid group of 
L-phenylalanine by a peptide bond. Ochratoxin B is a dechloro derivative of OTA and has a 
ten times lower to almost no toxicity compared to OTA (10, 11). Ochratoxin C is the ethyl 
ester of OTA and can be formed during the metabolism of OTA, obtaining the same toxicity 
like OTA (12). Beside the main forms mentioned, more OTA metabolites occur in nature, for 
example, derivatives of OTA and ochratoxin B esterified with methyl and ethyl groups at the 
free acid group (10, 11), hydroxylated forms of OTA (OH-OTA), like (4R)-OH-OTA,        
(4S)-OH-OTA and 10-OH-OTA (13) and analogues of OTA, which contain other amino acids 
than phenylalanine, such as serine, hydroxyproline, lysine and tyrosine (14). With regard to 
toxic damages in animals and humans, OTA is of most concern. Hence, the following sections 
will focus on OTA. 
 
OTA producing mould 
OTA production is dependent on various factors such as temperature, water activity            
(aw-value), pH-value and other environmental parameters, which are crucial for the growth of 
OTA-producing mould. OTA was originally described as a metabolite of Aspergillus 
ochraceus (15). Other Aspergillus species have been described as OTA producers, of which 
only A. carbonarius plays a quantitatively substantial role. The only OTA producing 
Penicillium species is P. verrucosum. Each one of the three main OTA producers require 
environmental conditions for optimal growth, which are summarized in Table 1. 
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Table 1:  Physical parameters for optimal growth of main ochratoxin A (OTA) producing mould 
OTA producing 
mould 
Range of 
temperature 
tolerance 
(°C, optimum) 
 
Preferred water 
activity (aw-value) 
Preferred 
pH 
Reference 
A. ochraceus 8-37 (24-31) 0.95-0.99 3-10 (16, 17) 
A. carbonarius 32-45 (40) 0.82 2-10 (18, 19) 
P. verrucosum 0-31 (20) 0.80 2-10 (20, 16) 
 
A. ochraceus was isolated from various foods and most commonly occurs in dried and stored 
food. These included, for example, dry beans and seeds, pepper, dried fruits and various nuts 
(aw 0.75-0.90) and also smoked salted dried fish (aw 0.75). A. ochraceus was also found in 
green coffee beans and their processed end-products like ready-to-drink coffee (21). To a 
lesser extent A. ochraceus was found in cereals and cereal products, cheese, spices, black 
olives and processed meat (16). About A. carbonarius relatively little is known. Its ability to 
produce OTA has been reported (22). A. carbonarius was mainly found on dried grapes and 
wine indicating that this species is the main source of OTA in those products. The capability 
of P. verrucosum to grow at lower temperatures affects its preferential distribution in 
geographical regions with a rather cool climate. Mainly grain is infested by P. verrucosum and 
as a consequence cereals and cereal products, including animal feed stuff, from Northern and 
Central Europe to Canada are contaminated with OTA. In a survey on Scandinavian farms, 
where pigs were suffering from nephritis, 67 of 70 barley samples contained high levels of P. 
verrucosum, of which 66 contained OTA (16). P. verrucosum also occurred on meat and 
cheese in Europe, but was not found in warmer regions or in other products than the above 
mentioned. 
 
Occurrence of OTA in contaminated food and feedstuff 
The "Joint FAO/WHO Expert Committee on Food Additives" (18) prepared a compilation of 
worldwide data available on OTA contamination of food and feed. The total number of 
samples was 23,167, of which 85 % were from Europe (Croatia, Denmark, Finland, France, 
Germany, Italy, Netherlands, Norway, Spain, Sweden, Switzerland and the UK), 7 % from 
South America (Brazil and Uruguay), 6 % from North America (Canada and USA), 1 % from 
Africa (Sierra Leone and Tunisia) and 1 % from Asia (Japan and Dubai). 1.4 % of all samples 
contained more than 5 µg/kg and 0.6 % more than 20 µg OTA/kg. For example, high average 
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concentrations were found in corn (7.5 µg/kg), moderate concentrations in dried grapes      
(2.3 µg/kg), instant coffee (1.4 µg/kg) and rye (1.2 µg/kg). Whereas low concentrations were 
found in wine (0.3 µg/kg), rice (0.06 µg/kg), animal products like meat, liver and sausage 
(0.05 µg/kg), and beer (0.03 µg/kg). The EU regulations for maximal allowance of OTA 
concentrations in food (23) are assessed in the range of 2-10 µg/kg for specified foodstuff, for 
example 10 µg/kg for dried grapes and instant coffee, 5 µg/kg for unprocessed grain, 3 µg/kg 
for processed grain (and products hereof) and  2.0 µg/kg for wine.  
Feedstuff for animals usually contain mixtures of home-grown and imported crops, such as 
groundnut, palm kernels, cottonseed, copra and soya. Any mycotoxins present in these 
products will contaminate the final product (24). A number of 811 feedstuffs were examined 
and OTA was detected in both, home-mixed and commercially produced feedstuff. 12.8 % of 
home-grown cereals destined for pig-feeding were contaminated with OTA. Barley                 
(< 5 mg OTA/kg) and wheat (< 2.7 mg OTA/kg) had OTA concentrations higher than the 
recommendation by the EU commission of < 0.25 mg/kg (25). In home-mixed pig-meal 12 % 
of the samples were contaminated with OTA (> 0.25 mg/kg) and only in 4 % of the 
commercially produced pig-feed OTA was detectable on a lower level than recommended. 
OTA was rarely detected in poultry (3 % positive for OTA, < 0.15 mg/kg) and cattle feeds   
(0.3 % positive for OTA, no results for concentration) (24). Transition of OTA from 
contaminated feedstuff to livestock and from produced animal products to the consumer 
("carry over"), as well as the transition of OTA from contaminated plant products to the 
consumer must be considered as well. In fact, OTA was found in Danish pork in an 
investigation in 1979 (26). For human daily OTA intake, however, food of vegetal origin is of 
greater significance compared to animal derived food. More than 50 % of the daily intake of 
OTA stems from cereals and cereal products and about 30 % of red wine, coffee and beer 
(27). Poultry and pork accounted for only 4 % and thus contribute little to human OTA 
exposure. Meat of ruminants appears not to be important for human OTA intake, because OTA 
is reduced by more than 80 % to the less toxic OTα in the rumen of the animals. Hence, 
transition of OTA into dairy products is attributed no significance (27). Nevertheless, OTA 
contamination of dairy products like cheese may occur after production (16).  
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2.1. Toxicokinetics and metabolism of OTA 
Generally, the extent of adverse effects of toxins depend on the route of exposition, dosage, 
bioavailability and biological half-life. Toxicokinetics of OTA involves absorption, 
distribution, metabolism and excretion. The following sections will focus on these aspects. 
The bioavailability of a substance is the pharmacological parameter, which is defined as that 
fraction of an administered dose, that reaches the systemic circulation in its original form. The 
oral bioavailability of OTA is 1.6 % in fish, 44 % in rat, 62 % in quail, 97 % in mouse, 57 % 
in monkey (28), 66 % in pig, 56 % in rabbit and 40 % in chicken (29, 30). 
 
Absorption and secretion of OTA in the gastrointestinal tract 
After oral consumption, OTA may be absorbed by passive diffusion in the stomach and the 
small intestine. OTA is lipid-soluble in its non-ionized form, hence, pH of the chyme and 
polarity of OTA determine the extent of OTA absorption by passive diffusion. OTA has two 
ionisable groups, which can exist in the ionized or non-ionized form under physiological 
conditions (31). OTA is a weak acid with a dissociation constant (pKa) of 7.1. The non-
ionized form will be mainly present in acidic solutions like in the stomach and will be partly 
absorbed by passive diffusion (32, 33). At neutral pH like in the the small intestine 50 % of 
OTA will be ionized (34). OTA is absorbed along the whole small intestine, whereas the 
highest capacity was found in the proximal jejunum (35, 36). Passive absorption of OTA is 
strongly influenced by the high binding affinity of OTA to plasma proteins, which generates 
an OTA gradient across the intestinal epithelial cells (35). Beside passive diffusion, active 
carrier systems are discussed to be involved in the intestinal absorption of OTA. The organic 
anion transport system (OAT, solute carrier family SLC22), organic anion-transporting 
polypeptides (OATP, solute carrier family SLCO, formerly SLC21), the large neutral amino 
acids transporter and the H
+
-dipeptide-cotransporter were  investigated in this context. They 
were not involved in intestinal OTA transport as neither intracellular accumulation nor 
transepithelial transport of OTA was affected in the presence of specific substrates of those 
transporters in Caco-2 cells (37). The results of an in vivo study with rats confirmed, that OTA 
is not absorbed via the H
+
-dipeptide-cotransporter or OATP1-transporter in the small intestine 
(36).  
Once absorbed into intestinal epithelial cells across the apical cell membrane, OTA may cross 
the basolateral membrane by passive diffusion and reach the blood or be actively transported 
back into the lumen (intestinal secretion) by efflux transporters. Thus, the amount of OTA 
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secreted by the whole intestine has been calculated to be similar to the amount secreted via 
bile (28).  
Three transporters, belonging to the adenosine triphosphate (ATP)-binding cassette (ABC) 
superfamily of transport proteins, are discussed to be involved in OTA resecretion across the 
brush-border membrane (multidrug resistance associated protein 2 = MRP2, breast cancer 
resistance protein = BRCP, and P-glycoprotein = P-gp). They act as energy-dependent efflux 
pumps, decreasing cellular concentrations of drugs and toxins, for example (37). MRP2, 
BCRP and P-gp are expressed in brush border membrane of enterocytes, in hepatocytes 
(canalicular membrane) and in kidney tubulus epithelial cells (38-42). P-gp transports mainly 
cationic compounds (40), whereas MRP2 mediates the transport of amphiphatic anionic 
conjugates (glutathione (GSH), glucuronid and sulfate conjugates) as well as unaltered 
lipophilic substances (43). Substrates of BCRP are hydrophobic compounds and hydrophilic 
conjugated organic anions (40, 44). Only few studies have addressed OTA as a substrate for 
efflux transporters. In Caco-2 cells and human embryonal kidney cells (HEK), OTA was 
transported by MRP2 and BCRP (9, 37, 45) and it was discussed whether OTA is also a 
substrate for P-gp (37, 45). Under experimental conditions, mimicking the in vivo pH 
situation (lumen side pH 6.0, blood side pH 7.4), OTA was absorbed across Caco-2 cell 
monolayers. In another study with Caco-2 cell monolayers, it was shown that OTA was 
extensively secreted by these cells across the apical membrane. But addition of the MRP2 
inhibitor indomethacin decreased secretion of OTA across the brush-border membrane which 
resulted in an increased absorption (37). The authors concluded, that due to the activity of 
MRP2 at the apical pole of intestinal epithelial cells, intestinal net absorption of OTA would 
be limited (37). In another experiment using Caco-2 cells, the effect of various polyphenols 
on OTA transport via MRP2 was examined (9). The cells were incubated with OTA           
(0.75 nmol/L, 7.5 nmol/L or 10 µmol/L) together with 50 µmol/L of chrysin, quercetin, 
genistein, biochanin A, catechin, epigallocatechin gallate, gallic acid, or  resveratrol, 
respectively. Chrysin, quercetin, genistein, biochanin A and resveratrol increased OTA 
transport at the basolateral site and increased intracellular concentrations by 80-150 %, which 
was explained by a competitive inhibition of MRP2 by these polyphenols or their metabolites 
(9). Hence, an inhibition of the energy-dependent efflux pumps would result in a higher net 
absorption of OTA. 
OTA not absorbed in its original form by the intestine, is metabolized to the less toxic OTα 
within the gastrointestinal tract. Phenylalanine is cleaved from OTA most likely by microbial 
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hydrolysis. Although in vitro studies revealed that OTA might be hydrolyzed by the pancreas 
enzymes carboxypeptidase A and chymotrypsin (29, 46, 47), investigations in rats treated with 
the antibiotic neomycin implicated, that the microbial flora plays a crucial role. After oral 
administration of the antibiotic, hydrolysis of OTA to OTα was clearly reduced as indicated 
by an increased OTA and a decreased OTα blood concentration and excretion, respectively, 
compared to controls (48). An extensive hydrolysis of OTA to OTα was also observed in 
rumen contents in vitro (49) and in caecum and colon contents of rats (48). In ruminants 
effective hydrolysis of OTA by the ruminal microflora is considered to be the cause for the 
high oral tolerance to OTA in ruminant species (50-52). The kidney and liver do not 
substantially contribute to the production of OTα from OTA (29). 
 
Tissue distribution of OTA 
Intestinally absorbed OTA is transported in the blood bound to serum proteins, mainly by 
albumin (30). This facilitates its passive absorption by generating a concentration gradient 
across the intestinal epithelial cells and explains the slow elimination of OTA from the body 
(53). Thus, a plasma "pool" of protein-bound OTA which can release OTA over a long period 
is formed (32). The biological half-life of OTA is species specific. It is 850 h in humans (54), 
230 h in rats (55), 88.8 h in pigs and 4.1 h in chickens after oral application (30). The biological 
half-life of OTA was significantly longer than of its main metabolite like OTα (56). Tissue 
distribution of intravenously applicated radioactive labelled OTA (
14
C-OTA) were conducted 
in mice and rats (57, 58). The highest amount of radioactivity was found in blood, kidney and 
liver and lowest concentrations in adipose tissue and brain (Table 2). The same ranking of 
OTA concentrations were found in pigs, chickens and rats (30, 59, 60). It was suggested, that 
reabsorption of OTA from the intestine into the circulation through enterohepatic circulation 
favours the systemic redistribution into different tissues (33, 57). 
                                                                                                                                                                              
Table 2:  Tissue content of OTA 1 hour after intravenous administration of 2.7 mg/kg b.w. 
14
C-OTA 
depicted as percentage of applicated dose in the whole organ and calculated concentrations 
in blood (µg/mL) and tissues (µg/g) (58) 
 Tissue OTA content OTA concentration  
 blood 43.5 46.8  
 kidneys   1.2 16.9  
 liver   6.1 15.1  
 adipose tissue   1.8 2.8  
 brain   0.1 1.4  
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Biotransformation of OTA in the liver 
Uptake of OTA into hepatic cells is mediated by OATP1 (61). There, a part of OTA is 
metabolized by enzymes of the "biotransformation pathway". Because cytochrome P450 
monooxygenases (CYP) play a central role in the biotransformation of xenobiotics (and 
endogenous metabolites as well) evidence for the involvement of CYPs in OTA metabolism 
will be subsequently illustrated in more detail. Investigations in liver microsomes of humans, 
pigs and rats indicate, that OTA is hydroxylated to (4R)- and (4S)-OH-OTA by CYPs (13, 62). 
In liver microsomes of rats, CYP1A1, CYP1A2, CYP2B1, CYP3A1 and CYP3A2 were 
involved in this transformation (63, 64). In contrast, in another study using rat liver 
microsomes, only low rates of (4R)-OH-OTA production by CYP1A1 and CYP3A4 were 
observed (62). In an in vivo study, conducted with Dark Argouti and Lewis rats over a period 
of two years, the expression of several CYPs before and after OTA administration by 
intragastric intubation (three times a week, 0.4 mg of OTA per kg body weight (b.w.)) was 
determined (65). In the liver, OTA induced CYP1A1, CYP1A2 and CYP2C11 expression in 
male animals of both strains, but only CYP3A1 was induced in dark Argouti and CYP2A2 in 
Lewis rats. In kidneys, CYP2B and CYP2C11 were induced in males of both strains and only 
CYP2A2 was induced in Lewis rats in response to OTA. Expression profiles of female Dark 
Argouti and Lewis rats differed from the males' ones (65). In addition, DNA adducts were 
found in the organs of OTA-treated animals in specific patterns and females had less DNA 
adducts than male rats of both strains. Based on these results, the authors concluded, that 
CYP1A1, CYP2A1, CYP2A2 and the female specific CYP2C12 were OTA-"detoxifying" 
enzymes, whereas CYP1A2, CYP2C11, CYP3A1, CYP2D, CYP2B and male specific 
CYP2C11 were "OTA-toxifying" enzymes (65). 
Further research efforts to identify the "OTA toxifying" CYPs were conducted using 
transgenic cell models with human CYPs. In murine NIH/3T3 fibroblasts, which were 
transfected with recombinant human CYP1A1, CYP1A2, CYP2C10 or CYP3A4, a dose-
dependent increasing mutation frequency of the cells was observed after incubation with OTA 
(66). However, no increased mutation rates were observed in cells expressing human 
CYP2D6 and CYP2E1 (67). In rabbit microsomes and in fibroblasts (NIH/3T3) expressing 
human CYP2C9, an increased DNA-adduct formation and loss of viability was observed, 
respectively (68, 69). It was postulated, that these "OTA-toxifying" CYPs generate OTA 
metabolites that are involved in DNA binding and renal damages of OTA (70-75). These 
bioactivated OTA metabolites, however, are not identified yet. The formation of OTA-derived 
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reactive quinones was suggested (76, 77). Thus, it was hypothesized, that OTA is activated by 
oxidation to the intermediate OTA-phenoxyl radical and then the OTquinone/OThydro-
quinone redox couple is formed by oxidative dechlorination of OTA (78). In one study, in 
which rats were fed OTA by gavage, OThydroquinone was detected in urine (79) but not in 
liver and kidney microsomal fractions from rats and mice (62, 64). 
A few studies investigated the conjugation of OTA by phase-II-enzymes. In an in vivo study 
with mice, treated with a single dose of radiolabeled [
3
H]-OTA, 28-68 % glucuronide and 
sulfate conjugates of OTA were found in bile. OTA-conjugates also have been found in liver 
(8-17 %) and in intestinal tissue (6 %) (33). Also in pigs fed with OTA contaminated feed, 
OTA conjugates were found in bile (80). In contrast, in liver microsomes of rats neither OTA 
nor (4R)-OH-OTA was a substrate for rat glutathione-S-transferase (62, 64).  
Taken together, some CYPs, which generate OH-OTA, are considered as "detoxifying" 
enzymes for OTA (CYP1A1, CYP2A1, CYP2A2, CYP2A12), whereas other CYPs 
(CYP1A2, CYP2C9, CYP2C10, CYP3A4) are considered as "toxifying" enzymes. But in 
both cases, the evidence is inconsistent. 
 
Transport mechanisms of OTA in the kidney 
The kidney is the primary target organ for OTA derived toxic effects because OTA is 
accumulated there. It was suggested that OTA is excreted via tubular secretion in the proximal 
tubules rather than glomerular filtration, because of its high binding affinity to plasma 
proteins (28, 81). In toad kidney, transepithelial secretion of OTA was a dose-dependent 
saturable process with a Km of 0.63 µmol/L and OTA accumulated in the cells and tubule 
lumen in a concentration-dependent manner, which implicated active transport processes 
(Figure 1) (81). Indeed, proximal tubular secretion of OTA involves active transport across the 
basolateral as well as the apical membrane (81, 82). Organic anions as OTA are transported by 
OAT across the basolateral membrane into cells in exchange with dicarboxylates                 
(e.g. α-ketoglutarate, succinate). The investigation of basolateral OTA transport in isolated 
kidney tubuli of rabbits and proximal tubule cells of opossum pointed to the involvement of 
OAT (81, 83). In studies with Xenopus laevis oocytes expressing the basolateral isoform 
OAT1, this transporter mediated the uptake of OTA, showing that OTA is a substrate of OAT1 
(84). Uptake of OTA via OAT1 was also found in murine proximal tubule cells (84). Other 
basolateral OAT isoforms, such as OAT3, were discussed in the transport of OTA across 
kidney tubule cell membranes during proximal tubular secretion (85-87). OTA transport 
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across the apical membrane into the proximal tubule is mediated by the already elucidated 
active efflux transporters MRP2, BCRP and possibly P-gp (see above)  (45, 88). 
 
 
 
Figure 1: Schematic illustration of the transport systems involved in OTA transport across the 
membranes of kidney proximal tubulus epithelial cells. ADP, adenosine diphosphate; ATP, 
adenosine triphosphate; BCRP, breast cancer resistance protein; DC, dicarboxylate; GSH, 
glutathione; MRP2, multidrug resistance associated protein 2; OAT, organic anion 
transporter; OATP, organic anion transporting peptide; OTA, ochratoxin A; P, phosphate; 
PEPT, H+-dipeptide co-transporter; P-gp, P-glycoprotein (modified according to 89) 
 
 
 
Whereas tubular secretion of OTA is limited to the proximal tubules, OTA is reabsorbed in the 
range of 75-90 % (90, 91) in all segments of the renal tubules, but via different mechanisms 
(Figure 2). 
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Figure 2: Schematic illustration of tubular secretion and reabsorption processes of OTA in renal 
tubules. The solid line stands for active transport processes, the dashed line for passive 
diffusion. The percentage values are the fraction of reabsorbed OTA in the respective 
segment under physiological conditions (91). OTA, ochratoxin A (modified according to 89). 
 
In a study with rats using in situ micropunction, OTA reabsorption in renal tubuli was 
examined at a concentration range of 0-0.05 mmol/L (90). 70 % of the infused OTA was 
reabsorbed in the proximal tubule in a partly saturable manner. 20 % of the infused OTA was 
reabsorbed in the distal tubule in a non-saturable manner. The reabsorption of OTA was pH-
dependent. When the pH-value of the infusion solution was raised from 6.0 to 7.4, OTA 
reabsorption was reduced from 70 to 40 % in proximal tubule and from 20 to 10 % in distal 
tubule (90). The apical transporters involved in the reabsorption process appear to be the H
+
-
driven dipeptide carrier in the proximal tubule and the kidney specific apical OATP (OAT-K1, 
OAT-K2) in the ascending limb of Henle's loop (91, 92). However, in distal tubule, OTA may 
be reabsorbed solely by non-ionic passive diffusion. The pH shift from 6.0 to 7.4 increased 
the dissociated fraction of OTA, which is not readily absorbed by passive diffusion due to its 
negative charge (90). Comparable results were achieved in other studies (91, 93, 94). For the 
entire tubule calculated, OTA reabsorption via H
+
-dipeptide co-transporter, OATP and non-
ionic passive diffusion accounted for 30 %, 20 % and 20 %, respectively (94). The remaining 
part may be a yet unidentified pH-dependent mechanism. OAT2 and OAT5, which are 
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localized in the brush border membrane of tubulus cells might be involved (85-87). Despite 
the extensive OTA reabsorption, in rabbit renal proximal tubule cells, tubular secretion of 
OTA was eightfold higher than reabsorption and thus, net secretion occurred (82). However, 
OTA reabsorption and its binding to proteins prolongs the retention time of OTA in the renal 
cells, giving it opportunity to act deleterious (95). 
Taken together, in  kidney nephrons, OTA is excreted via proximal tubular secretion, because 
protein binding hinders glomerular filtration. The transport system involved at the basolateral 
membrane would be OAT1/3. OTA is transported into the lumen by the efflux transporters 
MRP2, BCRP and possibly OAT2/5 located at the apical membrane. OTA is reabsorbed in all 
tubule segments, probably mediated by the H
+
-dipeptide co-transporter and OATP (OAT-K1, 
OAT-K2) in the proximal tubuli and by passive diffusion in the distal tubuli. 
 
Total excretion of OTA and OTA-metabolites  
OTA is eliminated with bile and urine, each pathway contributing about 50 % to total 
excretion (56). OTA excreted via feces is derived from biliary and intestinal secretion, 
respectively, whereby the latter accounts for the minor fraction (29). 120 h after a high single 
oral dose of OTA (15 mg/kg b.w.), the excretion of OTA and its main metabolite OTα 
accounted for 57 % of the total dose administered to rats. In that study, total excretion was 
allocated to 34 % (OTα 23 %, OTA 11 %) and 22 % (OTA 11 %, OTα 12 %) to feces and 
urine, respectively (29). After a dose of 6.6 mg/kg b.w. (96), the main metabolite excreted was 
OTα (25-27 %, in urine and feces) followed by OTA in its original form (6 %) and (4R)-OH-
OTA (1-1.5 %); after a dose of 0.5 mg/kg b.w. (55) the excretion of OTA and OTα was 14.7 % 
(6.3 % in urine and 8.4 % in feces) of the administered dose within 96 hours. OTA was the 
dominating form in feces (5.5 % vs. 2.9 %), whereas OTα was the dominating form in urine 
(4.2 % vs. 2.1 %).  
  
13 
2.2. Toxicity and toxicodynamics of OTA 
OTA toxicity varies considerably between species and within a species it is dependent on diet, 
age and sex (31). Values for the acute oral toxicity of OTA (LD50) are shown in Table 3. 
 
Table 3:  Acute oral LD50 doses for OTA in various species (31)  
 Species Oral LD50 (mg/kg b.w.)  
 mouse 46-58  
 rat 20-30  
 quail 17  
 guinea pig 8-9  
 rat neonatal 4  
 chicken 3.3  
 pig 1  
 dog 0.2  
 
Whereas rats and mice are considerably tolerant with respect to the acute toxicity of OTA, 
pigs and dogs are highly sensitive. In all studied monogastric species OTA had dose-
dependent nephrotoxic effects. In contrast, no LD50 values were reported for ruminants 
because they are much more tolerant to OTA due to effective bacterial cleavage of OTA in the 
rumen (97). 
Chronic toxicity of OTA was intensively investigated in pigs, because slaughtered pigs 
showed nephropathies after consuming OTA contaminated feed (98). Their kidneys were 
discoloured from usually red-brown to greyish-red, which was a result of fibrotic plaques in 
the interstitial gaps. Examinations of those kidneys revealed atrophic and ultra structural 
changes in tubules. The basal and brush border membranes were degenerated in proximal 
tubular epithelial cells (98). Controlled trials in pigs, using a daily oral intake of OTA       
(0.008 and 0.04 mg/kg b.w. per day) for 5 days (99), 3 months or 2 years (100) confirmed the 
above mentioned observations. In addition, an increased renal glucose excretion was found 
during the 2 year period of exposure to the mycotoxin (100). After 2 years of regular OTA 
intake (0.04 mg/kg b.w. per day), an advanced nephropathy without any renal failure was 
diagnosed (100). Similar results were observed in a study with young dogs. OTA was 
administered in capsules at doses of 0.1 or 0.2 mg/kg b.w. per day for 14 days. In those 
animals, no changes in renal function was observed, but their kidneys exhibited tubular 
necrosis and ultra structural changes in the proximal tubules. In addition, necrosis of 
lymphoid tissue of the thymus and the tonsils was discovered (101, 102). In studies with rats 
OTA-induced damages were dose-dependent; at doses of 15 µg/kg b.w. per day karyomegaly 
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of cells of the proximal tubules were observed and with increasing doses a decrease of the 
relative kidney weights and eosinophilia of the proximal convoluted tubules, rejection of 
proximal tubular cells, autolysis and changes in the rough and smooth endoplasmatic 
reticulum, thickening of the tubule membranes and growth retardation, respectively (103, 
104). Long-term studies (90 days, 2 years) with mice and rats resulted in renal cell carcinoma 
and adenoma after daily OTA doses of 3.5 to 7 mg/kg b.w. (104, 105). The doses for the 
lowest observed adverse effect level (LOAEL) and no observed adverse effect level (NOAEL) 
are summarized in Table 4. 
 
Table 4:  Doses of ochratoxin A (OTA) for LOAEL and NOAEL in long-term studies on OTA toxicity 
(106), based on a compilation from (18) 
Species Effect Duration of 
studies 
LOAEL 
(µg kg
-1
 
b.w. day
-1
) 
NOAEL 
(µg kg
-1
 b.w. 
day
-1
) 
Reference 
Mouse kidney tumours 2 y 4,400 130 (105) 
Rat karyomegaly of cells 
of proximal tubule 
90 d 15 Not 
demonstrated 
(103) 
 kidney tumours 2 y 70 21 (104) 
Pig impaired renal 
function 
90 d 8 Not 
demonstrated 
(100) 
 progressive 
nephropathy 
2 y 40 8 (100) 
 
The incidence of renal carcinomas and adenomas increased dose-dependently. Metastasis 
from renal and hepatic tumours was not observed. Rats and mice that died prematurely had 
kidney tumours, too (104, 105). Although the liver is often mentioned as a target organ for 
OTA toxicity, this organ was clinically effected only in severe cases and long term exposition 
as a liver tumour was manifested (104). In animal experiments, in which OTA clearly affected 
the kidney, the liver remained clinically unaffected (101, 107). However, it cannot be ruled 
out, that on molecular and/or metabolic level adverse changes will occur, although to a 
smaller extent than compared to kidney (108) and with less serious physiologic effects. 
Taken together, the main target tissue for OTA is the kidney. Damage begins at the level of 
proximal tubule cell membranes and continues with karyomegaly of proximal tubule cells, 
necrosis, deposits of fibrotic plaques in interstitial gaps and leads to macroscopic alterations 
of the kidney and disordered renal function (nephropathy). High chronic doses culminate in a 
deteriorated general condition. 
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Toxicodynamics describes the actions and interactions of an exogenous compound like OTA 
within an organism. For the above described degenerative alterations of kidney tissue caused 
by OTA, several mechanisms were postulated. 
At the beginning of OTA research, it was postulated, that OTA might interfere with amino 
acid metabolism of phenylalanine, because OTA contains a phenylalanine moiety. OTA was 
suggested to disrupt protein synthesis by interfering with the enzymes phenylalanine RNA 
synthetase and phenylalanine hydroxylase. Investigations in microorganisms, mammalian 
cells and in vivo studies proved the potency of OTA to inhibit this two enzymes, resulting in 
disturbed protein synthesis (109-111).  
Another hypothesis is that OTA forms DNA adducts and causes genotoxicity. In vivo as well 
as in vitro a dose- and time-dependent formation of DNA adducts was detectable (75, 112-
115). But the chemical structure of these adducts has not been elucidated yet and it is unclear 
if OTA is covalently bound to the DNA (34). Conflicting results were achieved in other 
studies, where the level of OTA-DNA adducts was below the limit of detection (62). The most 
common hypothesis is that OTA causes oxidative stress. Oxidative stress is known as an 
imbalance of the production of ROS, like superoxide anion radical (O2•) and hydroxyl radical 
and their elimination through antioxidant systems. ROS attack lipids, proteins, nucleotides as 
well as amino acids or biogenic amides and affect redox sensitive mechanisms in cell 
metabolism like cell signaling and gene expression which lead to cell damage and apoptosis 
(34, 116). Various studies indicated, that OTA induces lipid peroxidation in vitro (116-121) 
and in vivo in rats (116, 119, 122-125). Some authors assume, that OTA complexes with Fe
3+
, 
which enables the reduction of iron in the presence of the flavoprotein NADPH-CYP-
oxidoreductase. The OTA-Fe
2+
 complex may then generate hydroxyl radicals in the presence 
of oxygen, leading to lipid peroxidation in membranes (116-118). In another study, however, 
it was suggested that chelating of Fe
3+
 by OTA is not required for ROS generation (126). 
Irrespective of the chemical nature of OTA interaction with iron, the increased lipid 
peroxidation by OTA affects the permeability of the membrane for Ca
2+
 ions and affects the 
intracellular calcium homeostasis negatively. It causes an increased influx of calcium into the 
cells, a release from intracellular stores and consequently a disruption of calcium sensitive 
channels. A single high dose (10 mg/kg b.w.), or several smaller doses (0.5-2 mg/kg b.w.) per 
day of OTA led to an increased activity of the ATP-dependent calcium pump in the 
endoplasmic reticulum and the renal cortex cells (127). OTA, therefore, could interfere with 
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cellular functions that are under control of calcium, such as cellular signal transduction and 
neuronal functions. 
The ability of potent antioxidant compounds to reduce OTA-induced lipid-peroxidation was 
investigated in vitro and in vivo. When vero monkey kidney cells were pre-treated with 
superoxide dismutase (SOD) and catalase in combination 4 h prior to OTA exposition, lipid 
peroxidation measured as malonyl dealdehyde (MDA) production was reduced, although not 
prevented completely (120). In Madin Darby canine kidney cells, vitamin A (all-trans-retinol) 
and vitamin E (racemic α-tocopherol, α-TOC) inhibited OTA-induced ROS production in a 
concentration dependent manner (128). In vivo studies in rats and mice confirmed, that the co-
application of OTA and antioxidative compounds such as SOD, catalase (129), melatonin 
(124, 125) and cyanidin 3-O-β-D-glucoside (130) resulted in a significantly reduced lipid 
peroxidation as measured by the production of thiobarbituric acid reactive substances 
(TBARS). Antioxidants such as retinol, ascorbic acid and α-TOC, which are known to act as 
superoxide anion scavengers, prevented the induction of DNA damage by OTA in mice, given 
2 mg/kg b.w. OTA by gastric intubation. In kidney, pre-treatment with α-TOC decreased DNA 
adducts by 80 %, retinol by 70 % and ascorbic acid by 90 %, respectively (114). 
 
Impact of OTA on cell signaling and gene expression 
A new approach in understanding the molecular mechanisms of OTA toxicity is the 
investigation of OTAs influence on cell signaling and gene expression processes at tissue 
concentrations in nanomolar range (131). One cell signaling pathway, which is thought to be 
affected by OTA is the mitogen activated protein kinase (MAPK)-pathway. MAPKs are 
serine/threonine kinases and transduce signals from the cell membrane to the nucleus, finally 
influencing mRNA transcription. Physiologic activators of MAPK cascades are, for example, 
extracellular stimuli like growth factors, mitogens and inflammatory cytokines. Pathologic 
activators are oxidative stress, UV irradiation, heat and osmotic shock (132). Through the 
activated MAPK cascade, various cytosolic components can be affected. Main cellular 
reactions are inflammation, proliferation, differentiation and apoptosis processes. Three major 
MAPKs have been described: extracellular signal-reduced protein kinase (ERK), c-Jun N-
terminal kinase (JNK) and p38 MAPK (132). Several studies indicate, that OTA induced ERK 
(133) and JNK/p38 phosphorylation in vivo and in vitro (134-136). In most cases, ERKs 
seems to be linked to cell survival and JNK/p38 to inhibition of cell growth                                
and apoptosis (137). How OTA actually mediates the activation of MAPK cascades, however, 
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has not yet been elucidated. Probably, ROS stimulates redox-sensitive signaling molecules, 
downregulates specific MAPK-phosphatases and modifies expression of various genes via 
transcription factors (132). 
In recently conducted studies examining gene expression after OTA administration in rats, a 
regulation of several genes caused by OTA was observed. Downregulation of genes was the 
predominant effect and more genes in kidney than in liver were affected (108, 138-142). 
Genes encoding for proteins involved in energy metabolism, biotransformation, 
detoxification, transport and oxidative stress response were also downregulated (108, 138,  
139, 141). In contrast, genes encoding proteins involved in acute phase response, 
inflammation, DNA damage, DNA repair, apoptosis and cancer were upregulated (108, 138,  
139, 141, 143). A microarray study was conducted comparing gene expression profiles of 
cultured primary rat proximal tubular cells and tissues of male Wistar rats treated with each a 
low (5 µmol/L and 1 mg/kg, respectively) or a high dose of OTA (12.5 µmol/L and 10 mg/kg, 
respectively) for 24 or 72 h (141). Interestingly, gene expression profiles from the in vivo 
experiment described above differed from profiles obtained from cultured cells. Genes of 
metabolism, biotransformation and detoxification (e.g. CYP2D18) as well as transporter 
(OAT-K1, OAT) were downregulated in vivo, but not in vitro (141). In another work, male 
Fischer rats were administered a daily dose of 300 µg OTA/kg b.w. per diet and after 7 days, 
21 days, 4 months, 7 months and 12 months; thereafter, gene expression analysis of kidney 
and liver tissue were conducted (138). The early indicator gene for oxidative stress (144) - 
heme oxygenase 1 (HO-1, gene symbol Hmox1) - was upregulated in kidney but not in liver. 
In contrast to HO-1, genes of oxidative stress defence system were downregulated in kidney, 
like enzymes involved in glutathione synthesis (glutamate-cysteine ligase catalytic subunit, 
glutamate cysteine ligase, modifier subunit (GCLC), glutathione synthetase, γ-glutamyl 
transpeptidase). A similar study with male Fischer rats daily treated with OTA (500 µg/g b.w., 
per gavage) was conducted. After 7 and 21 days, respectively, gene expression profiles were 
analyzed (108). This study confirmed the aforementioned findings. In detail, the genes of 
oxidative defence system, which were downregulated were GCLC, glutathione S-transferase, 
theta 2, microsomal glutatione S-transferase 1 and the extracellular SOD3. Lühe et al. (141) 
also found, that the transcription factor hypoxia inducible factor 1 (HIF-1), which indicated 
oxidative stress, was upregulated, but genes of the antioxidant system like catalase and 
glutathione synthetase were downregulated. 
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Regarding CYPs, the microarray studies revealed, that several CYPs (CYP2J4, CYP2C, 
CYP2D9, CYP2D26, CYP213, CYP2C39) were downregulated and none upregulated (108, 
138). In a long term study by Pfohl-Leszkowicz et al. (65) investigating gene expression 
profiles of CYPs by the Western blot technique in Dark Argouti and Lewis rats after 
administration of OTA for 2 years (0.4 mg/kg b.w. by intragastric intubation three times  
weekly), it was shown, that CYP1A1, CYP1A2, CYP2A1, CYP2A2, CYP2C11 and CYP3A 
were upregulated and only CYP2B was downregulated in liver of male Dark Argouti and 
Lewis rats. In the kidney, CYP2A2 and CYP2C11 were upregulated.  
With respect to efflux transporters, the study of Marin-Kuan et al. (138)  revealed a 
downregulation of MRP2 at all time points, whereas P-gp was downregulated by OTA after 
seven days, switching to upregulation at the subsequent time points (138). This agrees  with 
findings of Arbillaga et al. (108). The ABC-transporter “multiple drug resistance transporter 
1” (MDR1, gene Abcb1a), an isoform of P-gp, was downregulated after 7 and 21 days. 
Interestingly, transporter, involved in OTA secretion and reabsorption in kidney tubuli like 
OAT1 (gene Slc22a6), OAT-K1 (gene Slco1a3/Slc21a4), OATP (gene Slco1a1/Slc21a1) and 
the organic anion/cation transporter (gene Slc22a12) were downregulated by OTA (108, 138). 
Hence, OTA might affect its own toxicokinetics, resulting in a slowed elimination of OTA and 
a prolonged retention in the kidney, thus favouring its acumulation (138). 
Many of the genes regulated by OTA share some regulatory elements. The common 
transcription factors involved are nuclear factor-erythroid 2 p45-related (Nrf2), hepatocyte 
nuclear factor 4 alpha (HNF4α), nuclear factor-k B (NFκB) and the activator protein (AP-1). 
In pig kidney epithelial cells (LLC-PK1) OTA decreased the transactivation of the 
transcription factors AP-1 and Nrf2 (145). Consequently, mRNA levels and activities of SOD 
and glutathione-S-transferase decreased and intracellular levels of ROS increased. Further 
results from an investigation on OTA effects in Fischer rats (daily dietary intake of               
300 µg OTA/kg b.w.) and from in vitro experiments using proximal tubule epithelial cells of 
Osborne Mendel rats (NRK cells, 3 and 6 µmol/L) indicated, that OTA inhibited Nrf2 activity, 
resulting in oxidative DNA damage. Pre-treatment of cell cultures with inducers of Nrf2 
prevented the inhibition by OTA (142). Based on those results, it was suggested, that OTA 
causes and/or enhances oxidative stress by down regulating gene expression of antioxidative 
enzymes through inhibition of the transcription factor Nrf2, thereby diminishing the cellular 
defence system. Consequently, susceptibility of cells to oxidative damage increased (142, 146, 
147). Another transcription factor, affected by OTA is HNF4α (138). HNF4α regulates genes, 
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encoding for proteins of biotransformation and transport proteins like OAT, OAT-K1 and 
OATP1. In contrast to Nrf2 and HNF4α, OTA significantly increased the activity of NFκB in 
cell cultures (134, 148-150). The NFκB family includes six members, which can form 
homodimers or heterodimers, of which p50/p65 (NFκB1/RelA) is the predominant one. When 
binding to the inhibitory protein IκBα, the NFκB-dimer is sequestered and translocation to the 
nucleus is prevented. Genes targeted by NFκB are mainly involved in cell death and 
inflammation (151). 
In conclusion, there is evidence, that toxic effects of OTA are centrally mediated by oxidative 
stress (Figure 3). Oxidative stress is increased because the cellular oxidant defence system is 
diminished by downregulation of gene expression on the level of the transcription factor Nrf2. 
In addition, the elimination of OTA is reduced due to downregulation of crucial transport 
proteins on the level of the transcription factor HNF4α. Consequently, OTA accumulates in 
the proximal tubulus cells, ROS levels increase, oxidative damage like lipid peroxidation of 
cell membranes or damage of DNA occur. In an advanced phase, cell integrity is lost, cell 
proliferation, differentiation and apoptosis might be induced. This might be, in part, mediated 
by MAPK signaling cascades, which are activated by ROS. Finally, oxidative DNA damage 
might turn into mutations and result in cell transformation and tumour development after 
long-term exposure. 
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Figure 3: Schematic illustration of the correlations of OTA, its influence on gene expression and 
oxidative stress. ↑ increase, ↓decrease. HIF-1, hypoxia-inducible factor 1; HNF4α hepatocyte 
nuclear factor alpha; HO-1, heme oxygenase 1; NFκB nuclear factor-k B; OTA, ochratoxin 
A; ROS, reactive oxygen species; SOD, superoxid dismutase; Nrf2, nuclear factor-erythroid 
2 p45-related. 
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3. Biological effects of the flavonol quercetin and its metabolites  
Flavonoids are secondary plant metabolites which are devided into six main classes, namely 
flavones, flavonols, flavanones, flavanoles (catechins), anthocyanidines and isoflavones 
(152). Quercetin is the most common flavonol, both with respect to its occurrence as well as 
its biological activities. In plants quercetin is extensively bound to sugar moieties. Due to 
glycosylation  the hydrophobicity of the aglycone is increased and storage in plant cell 
vacuoles is enabled (153, 154). Quercetin is glycosylated with glucose, arabinose, galactose, 
glucorhamnose, rhamnose and xylose, as well as with glucuronic and galacturonic acid (152). 
The sugar moieties are bound via O-β-glycosidic bond at the preferred position C-3, less often 
C-7 and seldom at the C-4' atom. Until now, about 200 different quercetin glycosides are 
known. They occur abundantly in onions (284-486 mg/kg) as isoquercetin (quercetin-3-O-β-
glucosid), spiraeoside (quercetin-4'-β-glucoside), quercetin-3,4'-diglucoside, isorhamnetin-4'-
glucoside and rutin (quercetin-3-O-glucorhamnoside) (155, 156). Other rich sources of 
quercetin are kale (110 mg/kg), french beans (32-45 mg/kg), broccoli (30 mg/kg) and apples 
(21-72 mg/kg) (155). In this chapter bioactivities of quercetin and quercetin metabolites will 
be described in more detail.  
In the beginning, evidence for positive health effects of quercetin derived from 
epidemiological studies (157-161). According to those studies, a high flavonoid intake 
correlated with protective effects regarding the risk of fatal and non-fatal coronary artery 
diseases, the risk of lung cancer, the incidence of asthma and the impairment of pulmonary 
functions in chronic obstructive pulmonary disease (see reviews 1-3). Single flavonoids such 
as quercetin, were investigated intensively in vivo and in vitro. As the postulated common 
mechanism of these diseases is mainly the imbalance of production and elimination of ROS, 
which results in oxidative stress, the antioxidative properties of quercetin is thought to be of 
central importance. 
 
Antioxidative activity of quercetin and quercetin metabolites 
Several studies have shown, that quercetin is able to influence the redox status of cells. This 
might occur due to direct activity as radical scavenger, or indirectly, e.g. reduction of pro-
oxidative metal ions, modulation of certain enzymes or regeneration of physiologic 
antioxidants (2, 8, 162). Quercetin may intercept electrons from reactive oxygen             
species (4, 5). For the ability to take part in one electron transitions the catechol (3',4'-
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dihydroxy)-structure of the B-ring, the C2, C3-double bound in combination with the 4-keto-
group and the hydroxyl groups in position 3, 5, and 7 are responsible (163-165). Furthermore, 
at least in vitro quercetin is able to chelate free metal ions like Cu
2+
 and Fe
3+
, which either act 
directly pro-oxidative or catalyze pro-oxidative processes (6-8). Interactions between the 
hydroxyl group at the C3-atom and the 4-keto-group of the C-ring are made responsible for 
this chelation reactions (6). An indirect antioxidative action of quercetin is due to its ability to 
interact and regenerate physiologic antioxidants like vitamin E and C, at least in vitro (166). 
In vitamin E deficient rats, dietary quercetin intake (100 mg/kg diet) for 10 weeks did not 
significantly affect markers of lipid peroxidation, while in the same study, quercetin was very 
effective in reducing lipid peroxidation in hepatic microsomes (167). However, in a feeding 
trial with pigs, receiving a low vitamin E diet (7 mg/kg), supplementation of quercetin        
(10 mg/kg b.w.) ameliorated oxidative processes as shown by reduced concentrations of 
TBARS and 8-iso-prostaglandine F2α (8-iso-PGF2α) and exerted a moderate vitamin E sparing 
effect (168). 
After reaching the systemic circulation, quercetin is mainly present as conjugated metabolites. 
Antioxidative activity of these metabolites might not be consistent with the antioxidative 
activity of quercetin aglycone. In general, the antioxidant activity of the aglycone is clearly 
reduced by its conjugation. It was shown, that conjugated quercetin metabolites inhibit Cu
2+
 
induced lipid peroxidation by half the magnitude compared to the quercetin aglycone (169). 
Nevertheless, after adaptation to a 0.2 % quercetin diet, total antioxidant status in plasma of 
rats was significantly increased (170). With respect to various quercetin conjugates, it was 
shown, that quercetin-7-glucuronide and quercetin-3-glucuronide are more efficient as 
antioxidants to reduce LPL-oxidation than are isorhamnetin-3-glucuronide or quercetin-3'-
sulfate (171, 172). In addition, quercetin-4'-glucuronide is a potent inhibitor of lipoxygenase 
(173). Methylated conjugates like isorhamnetin (3-methylquercetin), 3'-O-methyl and 4'-O-
methyl quercetin showed strong antioxidant activity (174-176). Compared to numerous in 
vitro studies, only few in vivo studies were conducted (167, 177-180). In humans, the 
beneficial health effects of quercetin were confirmed, but only one study was able to show 
improved in vivo oxidative stress markers (180) and another study showed increased plasma 
antioxidant capacity ex vivo (178).  
There is evidence that in addition to the above mentioned properties, quercetin's antioxidative 
effects are attributed to modulating gene expression. Thus, it was shown, that quercetin is able 
to increase the expression of the rate limiting enzyme of glutathione synthesis (181). 
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Glutathione is the most important endogenous cellular antioxidant and exists in the thiol-
reduced (GSH) and disulfide-oxidized (GSSG) form. It acts as the main cellular redox buffer 
and a shift in the ratio of GSH:GSSG may influence sensitive cysteinyl residues in 
polypetides (182). Glutathione is required for various cellular functions including scavenging 
of free radicals, reduction of peroxides or conjugation of electrophilic compounds (182, 183). 
It is postulated, that quercetin interacts with proteins of cellular signaling cascades and with 
trans-active elements of gene expression (transcription factors) (182). Many genes involved 
in endogenous antioxidant defence of cells contain the same specific DNA sequences at the   
5'-flanking promoter region called cis-active element, which is recognized by a specific 
transcription factor (182). Antioxidant enzymes, such as HO-1, NADPH:quinone 
oxidoreductase and γ-glutamyl cysteine synthetase are regulated by the transcription factor 
Nrf2. Nrf2 belongs to the family of basic region-leucine zipper transcription factors. It binds 
to the cis-active antioxidant responsive element (ARE) or the electrophile responsive Element 
(EpRE) located in the promoter region of target genes (184). It was shown, that quercetin 
induces Nrf2 related gene expression (185-188) and it was suggested, that quercetin deblocks 
this transcription factor from its inhibitor protein Kelch like erythroid cell-derived protein 
with CNC homology (ECH)-associated protein 1 (Keap1). As an underlying mechanism of 
these quercetin activities it was hypothesized that the pro-oxidative activity of quercetin, 
which was shown in vitro under certain conditions, might be responsible (189, 190). It is 
suggested, that quercetin is oxidized either enzymatically or spontaneously into a quinone, 
that can be reduced back to parental molecules meanwhile ROS would be generated (191). 
This generation of ROS by quercetin is thought to occur at a subtoxic level for cells, but to be 
strong enough to activate cellular defence mechanism mediated by Nrf2. Keap1 might sense 
ROS via thiol modification of its cysteinyl residues, which changes the conformation and 
releases Nrf2 from the complex. In addition, the degradation of Nrf2 by the 26S proteasome, 
which is supported by Keap1, is diminished and Nrf2 is stabilized (182, 184). In addition, 
phosphorylation of the Nrf2/Keap1 complex, triggered by kinase signaling pathways might be 
another possibility for the release of Nrf2 from the complex. The involved signaling pathways 
are considered to be MAPK, ERK, and phosphatidylinositide 3-kinases (PI3K). Their 
activation is required for the nuclear translocation of Nrf2 triggered by antioxidants (184). 
In addition, quercetin is a dietary protein kinase inhibitor (182). The inhibitory activity of 
quercetin is associated with its ability to compete with the binding of ATP to the nucleotide 
binding site of the kinases (192). It was shown in vitro, that quercetin reduced 
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phosphorylation of the kinases Akt and ERK at concentrations ranging from10 to 30 µM 
(193). Also, quercetin was able to reduce the kinase activity of PI3K to approximately 20 % 
of control values (194). In a study investigating the potency of 3'-O-methyl quercetin and 4'-
O-methyl quercetin to protect cardiomyoblasts against H2O2-induced oxidative stress, 
quercetin aglycone but not its O-methylated forms modulated the cellular signaling pathways 
PI3K/Akt and ERK1/2 and counteracted H2O2 cell damage. In this study, 3′-O-methyl 
quercetin and 4′-O-methyl quercetin were also able to reduce intracellular ROS production 
but not by modulating  PI3K/Akt and ERK1/2 signaling pathways (175). 
Other transcription factors modulated by quercetin resulting in antioxidant cellular defence 
are AP-1 and HIF-1. AP-1 is a dimeric transcription factor and belongs to the basic leucine-
zipper family. The protein families Jun
1
, Fos
2
, ATF
3 
and Maf
4
, again have numerous members 
which dimerize. The AP-1 transcription complex binds to the TPA (12-O-tetradecanoyl 
phorbol 13-acetate)-response element (TRE) or cyclic AMP response element. Regulating 
stimuli are pro-inflammatoric cytokines, growth factors, oxidative stress and tumour 
promoters. Target genes of AP-1 are involved in cell growth and cellular stress (184). 
Signaling pathways, that regulate AP-1 activity are the major MAPK and PI3K pathways. 
Beside the ability to interact with these signaling pathways, quercetin is thought to inhibit AP-
1 DNA binding, through inhibiting the JNK/stress-activated protein kinase (195-197). At low 
concentrations (< 50 µM), quercetin increased AP-1 activity in a prostate cancer cell line, but 
at high quercetin concentrations AP-1 was inhibited. This indicates that regulation of basal 
AP-1 activity by quercetin depends on its concentration (184). HIF-1 belongs to the basic 
helix-loop-helix protein family, too, and consists of two subunits (HIF-1ɑ and HIF-1β). The 
subunit HIF-1ɑ is expressed constantly, but triggered to 26S proteasome for ubiquitination 
after hydroxylation of certain proline residues (198, 199).  
If the oxygen concentration in cells decreases, HIF-1ɑ degradation is diminished due to 
decreased activity of the oxygen dependent prolylhydroxylases. HIF-1ɑ translocates to the 
nucleus and binds with HIF-1β to the HIF-1 responsive element. Target genes of HIF-1 are 
numerous and are involved in inflammation, regeneration of matrix, cell proliferation, 
differentiation, apoptosis, cell migration and adhesion. In in vitro studies, it was shown, that 
quercetin induced HIF-1 in a concentration and time-dependent manner (200-203).  
1
jun proto-oncogene, 
2
FBJ osteosarcoma oncogene, 
3
activating transcription factor, 
4
v-maf avian 
musculoaponeurotic fibrosarcoma oncogene homolog 
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The effect of quercetin was not due to its pro-oxidative property, but rather due to the 
chelation of Fe
3+
 ions, which are essential cofactors for the prolylhydroxylases. As a 
consequence HIF-1ɑ is stabilized by quercetin and translocates to the nucleus (200-204). 
 
Effects of quercetin on CYP1A1 and CYP1A2 
Another metabolic pathway affected by quercetin is the biotransformation pathway. There are 
some in vivo (205-207) and several in vitro (208-215) studies  indicating that quercetin 
modulates expression and activity of phase-I and phase-II-enzymes as well as of efflux 
transporter. Because the present study focuses on the phase-I-enzyme CYP1A and the efflux 
transporters, these will be considered in more detail subsequently. 
Isoforms of CYP1A are expressed in the liver (CYP1A2) and the intestine (CYP1A1). 
Treatment of breast cancer cells (MCF7) with quercetin (1-20 µmol/L) resulted in a 
concentration- and time dependent increase in the amount of CYP1A1 mRNA (208). 
Quercetin also caused a concentration and time dependent increase in CYP1A1 enzyme 
activity as measured with the ethoxyresorufin-O-deethylase (EROD) activity assay (208). In 
Caco-2 cells, quercetin acted as an inducer of CYP1A1 expression on the mRNA as well as 
protein level at a high concentration of 100 µmol/L and an incubation time of 48 h (209). 
Genes of the CYP enzymes contain xenobiotic responsive elements in their promoters and 
may be regulated in part by the aryl hydrocarbon receptor (AhR), which is a ligand-activated 
transcription factor (216). Flavonoids such as quercetin have a basic chemical structure with 
some poly aromatic hydrocarbons in common. Therefore, it is plausible, that quercetin 
interacts with cellular defence systems such as phases I detoxification enzymes (182, 217, 
218). Quercetin binds directly to the AhR (208, 219) and induces gene expression of 
CYP1A1/2 and other proteins of the biotransformation pathway (210). The dose-dependent 
inducing effect of quercetin on the CYP1A1 activity, measured with the EROD essay was 
confirmed in Caco-2 cells (211). But in contrast to previous results quercetin did not affect the 
CYP1A1 mRNA concentration. The authors of that study suggested, that quercetin was not a 
AhR ligand in intestinal cells and that it rather acted on a posttranscriptional level. However, 
in yeast cells, quercetin inhibited the bioactivation of a carcinogenic heterocyclic amine (3-
amino-1-methyl-5H-pyrido[4,3-b]indole) with an IC50 of 0.35 µmol/L (220). In human 
hepatocytes (Hep G2 cells), which were treated with 10 µm/L benzo[a]pyrene for 18h in the 
presence and absence of quercetin, the decrease in CYP1A1 enzyme activity indicated that 
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quercetin inhibited benzo[a]pyrene induced CYP1A1 expression through blocking the AhR 
(212).  
In a study using a perfused rat liver model , quercetin exerted an inhibiting effect on CYP1A2 
activity (221). Quercetin also inhibited CYP1A2 in a recombinant CYP1A2 enzyme 
preparation with an IC50 value of 7.5 µmol/L (213). Quercetin was not potent inducer of 
CYP1A2 in S9 fractions of rat liver (222). In Chinese hamster V79 cells expressing rat 
CYP1A2, 10 µmol/L quercetin also inhibited rat CYP1A2 (214). In transfected HepG2 cells 
quercetin inhibited mouse CYP1A2 and human CYP1A2, determined with the                        
7-methoxyresorufin-O-dealkylation (MROD) assay (215). 
Taken together from the studies conducted so far, at least quercetin aglycone exerted an 
inducing effect on CYP1A1 in the intestinal epithelial cells by binding to the transcription 
factor AhR, but may act as an competitive inhibitor when co-applied with substrates of 
CYP1A1. In liver, quercetin aglycone inhibited CYP1A2 activity. 
 
Effects of quercetin on MRP2, BCRP and P-gp 
In numerous studies interactions of quercetin with ABC transporters, mainly P-gp, were 
investigated. Early studies demonstrated that quercetin efﬁciently inhibited the transport 
activity of P-gp in a dose-dependent manner (223, 224). However, some studies indicated 
stimulating effects of quercetin on P-gp (225). It was demonstrated, that at low concentrations 
(10µmol/L) quercetin decreased, while at high concentrations (50 µmol/L) it increased the 
steady-state accumulation of the P-gp substrate vincristine in mouse brain capillary 
endothelial cells (MBEC4 cells) (226). Similar effects were achieved in vivo. In mice, 
quercetin decreased vincristine concentrations in brain at a concentration of 0.1 mg/kg b.w., 
but significantly increased it at a concentration of 1 mg/kg b.w. (226). The explanation for 
this biphasic effect was, that low concentrations of quercetin indirectly stimulate P-gp by 
increasing P-gp phosphorylation while high concentrations of quercetin inhibit P-gp (226). 
However, a majority of the more recent studies have indicated that quercetin has an inhibitory 
activity on P-gp mediated transport. For example, co-administration of quercetin and 
moxidectin subcutaneously, increased moxidectin bioavailability in lambs (227). Quercetin 
also increased the oral bioavailability of paclitaxel in rats (207, 228) and the oral 
bioavailability of digoxin in pigs (229). The inhibitory effect of quercetin on P-gp is 
explained with interaction at different binding sites of P-gp. A biologically active ABC 
transporter protein contains two transmembrane domains and two ABCs or nucleotide binding 
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domains (230). Transmembrane domains are the substrate-binding sites and/or substrate 
translocation pathways through the membrane to the efﬂux substrates. Nucleotide binding 
domains are located at the inner side of the cell, participating in ATP binding and hydrolysis 
being the driving force for active transport (231). Inhibition of either transmembrane domains 
or nucleotide binding domains may cause the impairment of P-gp function. As quercetin itself 
is a P-gp substrate (229, 232), it was postulated that quercetin may competitively or 
noncompetitively interact with other substrates for substrate-binding sites of P-gp. Quercetin 
and rutin were shown to directly interact with the ATP-binding site and the substrate-binding 
site, leading to inhibition of ATP-binding and ATPase activity and consequently inhibition of 
P-gp function and efflux of xenobiotics (233). In addition, quercetin is capable of decreasing 
P-gp expression in a dose-dependent manner (234). It was also shown, that quercetin inhibited 
the up-regulation of P-gp protein and mRNA in response to hyperthermia involving a heat 
shock factor (235). A recent study confirmed these findings. At a concentration of 12 µmol/L 
quercetin inhibited the mRNA synthesis and also the transport activity of P-gp in a pancreatic 
carcinoma cell line (236). It was suggested, that the mode of action could be the inhibition of 
heat shock factor DNA-binding activity (237) or downregulation of the beta-catenin signaling 
pathway (238).  
However, regarding the interaction of quercetin with P-gp in vivo, it should be considered, 
that most of these P-gp substrates are also substrates for CYP3A. It was shown, that quercetin 
is also capable to inhibit CYP3A. Hence, a distinct correlation of quercetin effects on CYP3A 
and P-gp activity in the above-mentioned studies is difficult (239). Nevertheless, for the 
physiologic outcome, in vivo results are more predictive than in vitro experiments. 
Furthermore, the concentration of quercetin aglycone in the systemic circulation would not be 
high enough for significant P-gp interaction and the quercetin glucuronide and sulfate 
conjugates may not interact with P-gp because these metabolites are organic anions and not 
preferred substrates of P-gp (239). Anyway, the aglycone which may be released in the 
intestine from the natural glycosides, could be present in concentrations high enough to 
inhibit intestinal P-gp.  
Quercetin also affects the efflux transporter MRP2 and BCRP. The conjugated metabolites of 
quercetin (glucuronides and sulfates) are MRP2 substrates (42, 240). Since these metabolites 
can reach a high concentration in the systemic circulation after supplementation, they could 
possibly inhibit MRP2 resulting in decreased biliary or renal excretion of other MRP2 
substrates (239). In fact, quercetin conjugates inhibited the transport of OTA in Caco-2 cells at 
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a concentration of 50 µmol/L (9). In recombinant membrane vesicles of the insect cell line 
Sf9, quercetin inhibited transport of the dye calcein mediated by MRP2 to 35 % (241). A 
mixture of quercetin metabolites (84 % 7-O-glucuronosyl quercetin and 10 % 3-O-
glucuronosyl quercetin, 1 % quercetin aglycone, some other minor conjugates) exerted a 
strong inhibitory effect of 95 %. In contrast to the inhibiting effects reported in the above 
mentioned studies, quercetin induced MRP2 mRNA synthesis in Caco-2 cells at high 
concentrations of 50 µmol/L and 100 µmol/L (242), but not in hepatocytes (HepG2) (243). 
The gene expression of the Abcc2-gene encoding for MRP2 is regulated by Nrf2 (244). As 
elucidated above, quercetin interacts with this transcription factor, hence it might be a 
possible mode of action. 
Quercetin can interact directly with BCRP and modulate its transport activity. It was observed 
that quercetin down-regulated the beta-catenin signaling pathway, which lead to a decreased 
expression of BCRP at the blood-brain barrier (238). It was also observed, that quercetin 
inhibited BCRP-mediated transport of mitoxantrone in human lung carcinoma cells (NCI-
H460) at a concentration of 50 µmol/L (245) and in epithelial breast cancer cells (MCF7) at a 
concentration of 30 µmol/L (246). In contrast, quercetin induced BCRP mRNA synthesis at a 
concentration of 25 µmol/L in Caco-2 cells (247). Further tests indicated, that the induced 
BCRP protein was functionally active. The authors suggested a regulation via AhR-dependent 
signaling pathways. 
Taken together, quercetin mainly exerts inhibiting effects on ABC transporters via different 
mechanisms, namely binding to ATP-binding sites, competitive inhibition, down-regulating  
β-catenin signaling cascade. At high concentrations, however, especially in intestinal cells 
(Caco-2 cells) an induction of MRP2 and BCRP gene expression through the transcription 
factors Nrf2 and Ahr, respectively, appears to be possible. 
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4. Materials and Methods 
4.1. Animals and treatment 
Experiment 1: Influence of quercetin on the toxicokinetics of OTA 
Eighteen growing male F344 Fisher rats (Charles River Lab., Sulzfeld, Germany) were 
acclimatized for a period of seven days to the conditions of the animal housing facility (room 
temperature 22 ± 2°C, 55 ± 5 % relative humidity, 12 hour dark/light cycle). During the 
adaptation period, a basic diet (see below) and tap water were offered for ad libitum intake. 
For the feeding trial of 6 days, the animals were randomly divided into two groups (OTA and 
OTA+quercetin (Q)-treated group, n = 9, each) with an average initial body weight of       
202.0 ± 8.1 g and 204.0 ± 10.1 g, respectively. The animals were housed individually in 
metabolism cages. The diets were fed restrictively (~70 % of ad libitum intake, 13 g/d) to 
ensure similar OTA intake in both feeding groups. Feces and urine were completely collected 
daily. Urine was acidified to pH 2-3 with 10 % (v/v) H3PO4 during collection. At the end of 
the feeding period, animals were anesthetized with isofluran (Abott GmbH, Wiesbaden, 
Germany) and euthanized by exsanguination. Blood was collected in EDTA-containers 
(Monovette®, Sarstedt, Nümbrecht, Germany) and plasma was immediately prepared by 
centrifugation (10 min, 4000 x g, 4 °C). In addition, tissue samples of liver, kidney, musculus 
quadrizeps and brain were taken. Fecal and urinary samples, blood plasma and tissues were 
stored at -20 °C until analyses.  
 
Experiment 2: Influence of quercetin on the mechanisms of OTA-toxicity 
Forty-eight growing male F344 Fisher rats (Charles River Lab., Sulzfeld, Germany) were 
acclimatized for a period of seven days to the conditions of the animal housing facility (room 
temperature 22 ± 2°C, 55 ± 5 % relative humidity, 12 hour dark/light cycle). The basic diet 
and tap water were provided for ad libitum intake during the adaptation period. 
For the experimental period of 23 days, the animals were randomly divided into four groups 
(control, OTA, quercetin, and (OTA+Q)-treated group, n = 12, each) with an average body 
weight of 161.3 ± 10.8 (control), 163.9 ± 10.0 (OTA), 162.5 ± 8.9 g (quercetin), and          
162.2 ± 10.3 g (OTA+Q), respectively. The animals were housed in pairs in macrolon cages 
on filter paper, which was changed daily. During the trial, feed and water consumption was 
measured daily and feed and water was also replaced daily; body weight was measured 
weekly. After a period of 24 days the animals were anesthetized with isofluran (Abott GmbH, 
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Wiesbaden, Germany) and euthanized by decapitation. Blood samples were collected in 
lithium-heparin container (Monovette®, Sarstedt, Nümbrecht, Germany) and blood plasma 
was immediately prepared by centrifugation (10 min, 4000 x g, 4 °C). Tissue samples of liver, 
kidneys, musculus quadrizeps, brain and small intestine were taken immediately and were 
shock frozen in liquid nitrogen within 5 minutes to avoid RNA-degeneration. Plasma and 
tissue samples were stored at -80 °C until analyses. 
 
All animal experiments were approved by the Ministry of Agriculture, the Environment and 
Rural Areas of Land Schleswig-Holstein, Germany (V 312-72241.12-25 (49-4/09)). 
 
4.2. Diets 
The experimental diets were based on a synthetic, balanced, flavonoid-free, powdered diet for 
adult rats (C1000, Altromin, Lage, Germany) containing (as fed basis) 58.2 % carbohydrates, 
17.6 % proteins, 5.1 % fat, 4.5 % fiber and 14.6 MJ/kg metabolisable energy. Because a high 
dietary vitamin E concentration might mask quercetin derived antioxidative effects, the 
vitamin E content of the diet was reduced to 30 mg/kg, covering the physiological demand. 
The experimental diets contained OTA and/or quercetin (as quercetin dihydrate, Roth GmbH 
& Co. KG, Frankfurt, Germany) as depicted in Table 5. As source for OTA, OTA-
contaminated wheat (2.5 mg OTA/g) was used, which was produced by inoculation of wheat 
with Aspergillus ochraceus NRRL 3174 as previously described (248). The dietary 
concentration of OTA was calculated to achieve a daily intake of 0.6 mg/kg b.w., a dose which 
has been used in several previous toxicokinetic studies and was not associated with any short-
term morbidity and mortality (249). The supplementation level of quercetin was chosen 
according to the in vitro studies by Sergent et al. (9) in which only ratios of quercetin:OTA 
higher than 5:1 caused increased OTA absorption and accumulation.  
 
Table 5:  Supplementation of the experimental diets  
Supplement (g/kg) Control Quercetin OTA OTA+Q 
quercetin - 0.100 - 0.100 
OTA - - 0.010 0.010 
OTA, ochratoxin A; OTA+Q, OTA and quercetin fed group 
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4.3. Analysis of OTA and OTα 
Because daily amounts of feces per animal were too small for analysis, feces obtained during 
the 6 days feeding period were pooled per animal, freeze-dried (-80°C, 25 h; Beta I, Martin 
Christ GmbH Co. KG, Osterode, Germany) and homogenized in a mortar before analysis. 
Extraction of OTA and OTα from blood plasma, feces, urine and tissues was performed as 
described previously (27). For sample preparation, diluted plasma samples (0.5 mL of plasma 
added to 1.5 mL of 145 mM NaCl solution), or 250 mg of freeze-dried feces (acidified to a pH 
of 2.3 with 6 M HCl, Sigma-Aldrich, Munich, Germany), or  0.5 mL of thawed urine samples, 
respectively, were mixed with 10 mL of a solution containing 0.05 M HCl and 100 mM 
MgCl2 (Sigma-Aldrich, Munich, Germany). After the addition of 10 (plasma and urine) or 15 
mL (feces) chloroform (Mallinckrodt Baker, Griesheim, Germany), respectively, the mixtures 
were shaken for 30 min. Samples were centrifuged at 10,000 × g for 15 min (plasma) or       
30 min (feces and urine) at 2 °C. After removal of the upper water layer by suction (KNF 
Neuberger Laboport®, Trenton, NJ, USA), deionized water was added to the chloroform 
fractions (plasma and urine samples 2 mL, feces samples 3 mL). Samples were shaken for 5 
min, and centrifuged at 4000 × g for 10 min at 2 °C. After removal of the water layer, 4 mL 
(plasma samples) or 5 mL (urine or feces samples, respectively) of the chloroform fraction 
were evaporated until dryness (SpeedVac AES 1010, Savant Instruments, Holbrook, NY, 
USA). Prior to high pressure liquid chromatography (HPLC) analysis, the samples were 
reconstituted in 1 mL (plasma, urine) or 2 mL (feces) of methanol (Mallinckrodt Baker, 
Griesheim, Germany). For extraction of OTA from tissue samples, one whole kidney (approx. 
0.7 g), 1 g of liver, 1 g of muscle, or 0.7-1 g of brain were homogenized (Potter S, B. Braun 
Melsungen AG, Melsungen, Germany) in 5 mL of 0.1 M sodium bicarbonate solution and 
were added by 5 mL of 0.1 M sodium bicarbonate solution, 500 µL of 2.25 M ortho-
phosophoric acid (Carl Roth GmbH & Co. KG, Frankfurt, Germany) and 12 mL chloroform. 
The samples were shaken for 30 min and centrifuged for 30 min at 10 000 × g at 2 °C. After 
removing of the upper water layer, the chloroform layer was washed with 1.5 mL of deionized 
water and constantly shaken for 10 min before centrifugation at 4000 × g for 10 min at 2 °C. 
Five milliliters of the chloroform layer were evaporated until dryness. Prior to HPLC analysis, 
the samples were reconstituted in 1 mL of methanol. All samples were determined in double. 
OTA and OTα contents of tissues, urine and feces were determined by HPLC with 
fluorescence detection as described earlier (27). 
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The HPLC system (Waters, Eschborn, Germany) consists of an autosampler (Waters 717 plus 
Autosampler), gradient pump (Waters 600E Multisolvent Delivery System), a fluorescence 
detector (Waters 474 Scanning Fluorescence Detector), a degasser (Waters In-line Degasser) 
und a column oven (Millipore/Waters TCM Column Oven System). A sample aliquot of 25 μL 
was injected by the autosampler. The separation of ochratoxins was performed by a             
250 mm × 4.6 mm (I. D.) 4 μm Nova-Pak-C18-column (Waters) with an upstream 20 mm × 
3.9 mm (I.D.) 4 μm Nova-Pak-Precolumn (Waters). The flow rate was 1.5 mL/min with an 
oven temperature at 40 °C. The fluorescence detection was carried out at an excitation 
wavelength of 330 nm and an emission wavelength of 450 nm. To facilitate the separation of 
ochratoxins, a gradient elution was used. The fluids were “solvent A” (acidified ultrapure 
water with H3PO4 to pH 2.1) and “solvent B” (methanol/isopropanol 90/10, v/v). The 
following gradient was programmed: minute 0 to 12: 50 to 25 % solvent A, minute 12 to 12.1: 
25 to 10 % solvent A, minute 12.1 to 17.0: 10 % solvent A, minute 17.0 to 17.1: 10 to 50 % 
solvent A, minute 17.1 to 22: 50% solvent A. Of each, the missing part of 100 % consisted of 
solvent B. 
The standards were prepared according to the AOAC method 970.44 (250). After calibration 
of the spectrophotometer with kalium dichromate (K2Cr2O7), OTA was solved in ethanol. 
Based on the molar absorption coefficient of 5500/mol/cm at 330 nm for OTA, the OTA 
concentration was determined spectrophotometrically. Afterwards, the standards were 
evaporated until dryness and methanol was added until concentrations in the range of     
15.48-173.14 nmol/l were adjusted. The identification of OTA was based on the retention 
times of the standards. The retention time for OTA in this method was 11.5 minutes. The 
quantification of OTA was calculated by the integration of the area under the curve of the 
OTA-peak (Millenium Chromatography Software, Waters, Eschborn, Germany). The absolute 
value of the area under the curve was devided through the regression factor, which was 
determined using the calibration curve of the standards. The result was the OTA concentration 
of the examined sample. For each sample run (with a maximum of 42 samples) an own 
calibration curve was created. The minimum detectable level for both OTA and OTα was       
1 ng/mL in plasma, urine and feces and 1 ng/g in tissue samples. Recoveries were estimated 
on the basis of recovery of OTA and OTα from spiked samples and were 95 % for plasma, 
urine and feces and 88 % for liver, kidney, brain and muscle. OTα concentrations were stated 
as OTA equivalents (molecular weight of OTA/molecular weight of OTα (403/256) × µg of 
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OTA) and total OTA concentrations were calculated as the sum of OTA and OTA 
equivalents. 
 
4.4. Analysis of α-TOC  
Concentrations of α-TOC in plasma, liver, kidney, muscle and brain were determined by 
HPLC with fluorescence detection (251). α-TOC concentrations were quantified using 
authentic α-TOC (Merck KGaA, Darmstadt, Germany) as an external standard. All 
measurements were performed in duplicate.  
For precipitation of proteins, diluted plasma samples (100 µL), or tissue samples (100 mg) 
were mixed with 2 mL of a 1% ethanolic ascorbic acid solution (w/v, Sigma-Aldrich GmbH, 
Steinheim, Germany) and added to 800 µL (plasma) or 700 µL (tissue) of ultrapure water 
(Merck KGaA, Darmstadt, Germany). For tissue samples only, 300 µL of saturated potassium 
hydroxide solution (56.5 g KOH ad 50 mL) were added, the samples incubated for 30 min  
(70 °C) in a shaking waterbath and cooled down in an ice-bath. To all samples 50 µL of a    
0.1 % ethanolic BHT-solution was added (w/v, Merck KGaA, Darmstadt, Germany) to 
prevent oxidative changes. 
To extract α-TOC, each sample was mixed with 2 mL hexane (Merck KGaA, Darmstadt, 
Germany) for 30 seconds manually and centrifuged for 5 minutes (2000 x g, 4°C, 5810 R, 
Eppendorf, Hamburg, Germany). 1 mL of the hexane phase was removed with a pipette, 
transferred into an Eppendorf-cup and vaporised at room temperature until dryness (Savant 
SpeedVac® System AES 1010, Global Medical Instrumentation, Minnesota, USA). The 
residue was solved in 250 µL of a methanol-water mix (98:2, v/v) and directly used for 
HPLC. 
The HPLC-system used was manufactured by Jasco (Gross-Umstadt, Germany) and consisted 
of a pump (PU-1580), autosampler (AS-2057 Plus) and a fluorescence detector (FP-1520).   
40 µL of each prepared sample was injected into the HPLC system. The stationary phase 
consisted of a  Waters Spherisorb ODS-2 column (100 x 4,6 mm, particle size 3 µm, Sigma-
Aldrich GmbH, Taufkirchen, Germany). The mobile phase was a methanol-water mix     
(98:2, v/v) and had a flow rate of 0.8 mL/min. The column was temperated at 25 °C in a 
column oven. The fluorescence photometric determination of the α-TOC concentration 
occurred at an excitation wavelength of 296 nm and an emission wavelength of 325 nm. For 
determination of α-TOC concentrations, a standard curve was calculated. A defined mass of 
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DL-α-TOC (Merck KGaA, Darmstadt, Germany) was solved in 20 mL of ethanol and 
successively diluted with a 0.005 % methanolic BHT-solution (w/v). Over the studied 
concentration range of 1.08 to 21.60 µg α-TOC/mL was a linear relationship between the 
concentration and the α-TOC peak area (Figure 4). Analysis of chromatographic data was 
performed using the Borwin Chromatography Software (Version 1.5, Jasco, Gross-Umstadt, 
Germany).  
Figure 4: Exemplary standard curve for the determination of α-TOC concentrations in plasma and 
tissues; R
2
, coefficient of determination. 
 
4.5. Analysis of 8-Iso-PGF2α 
Isoprostanes are prostaglandin-like compounds and consist of numerous isomers. 8-Iso-PGF2α 
is an 8-epimer of prostaglandin F2α and is produced in vivo by non-cyclooxygenase dependant 
mechanisms like peroxidation from arachidonic acid (252). It is used as an in vivo-marker of 
oxidative stress. In vivo lipid peroxidation was assessed by measuring the plasma 
concentrations of 8-iso-PGF2α with an enzyme immuno assay (EIA, Direct 8-Iso-
Prostaglandin F2α, Assay Designs, Michigan, USA) according to manufacturer’s protocol. All 
measurements were performed in triplicate. This assay is based on the principal of 
competitive binding. 8-Iso-PGF2α in the sample (or standard) competes with a defined amount 
of 8-Iso-PGF2α-phosphatase conjugates for a limited number of 8-Iso-PGF2α-specific binding 
sites of an antibody complex (which consists of primary and secondary antibodies) localised 
on a microtiter plate. 
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For detection of total 8-Iso-PGF2α-concentration in the sample, which includes free and 
esterified 8-Iso-PGF2α with phospholipids, 200 µL of blood plasma were incubated with 50 µL 
of a 10 mol/L sodium hydroxide solution at 45 °C in a water bath, added to 50 µL 
hydrochloric acid (12.1 mol/L) and centrifuged (4 °C, 20.800 x g). The supernatant was 
removed and adjusted to pH = 7 with a sodium hydroxide solution (2 mol/L). Of each sample, 
50 µL were used for the EIA. The concentration range covered from the standard curve was 
from 160 to 1,000,000 pg/mL (Figure 5). 
 
Figure 5: Exemplary Standard curve for the determination of 8-iso-PGF2α in blood plasma; bound 8-
iso-PGF2α  (%, B/BO),▲;  optical density, ● 
 
 
4.6. RNA isolation, real-time quantitative RT-PCR and calculation of relative 
mRNA concentrations 
Of five animals per group, frozen tissues (liver, kidney, proximal jejunum) were ground in a 
mill cooled with liquid nitrogen. Total RNA was isolated from tissues according to 
manufacturer’s protocols (Qiagen, Hilden, Germany) using the RNeasy® Lipid Tissue Mini 
Kit for intestinal and hepatic tissue and the RNeasy® Fibrous Tissue Mini Kit for kidney 
tissue. For hepatic and intestinal tissues, samples of 35-40 mg were homogenized in QIAzol 
Lysis Reagent (1000 μL) for 15-90 s with the Ultra Turrax (Miccra D1, ART Prozess- & 
Labortechnik GmbH & Co. KG, Müllheim, Germany). The samples were left to rest for 5 min 
at room temperature. 200 µL of chloroform was added and gently swung for 15 s. After 2-3 
min rest period at room temperature, the homogenate was centrifuged (15 min, 4°C, 12000 x 
g). The upper, clear (aqueous) phase was transferred into new Eppendorf-cups (600 µL). 
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Ethanol (70 % v/v, 600 µL) was added and immediately mixed with a vortex-mixer. For 
purification of RNA, 700 µL homogenate was transferred on a mini-column in a 2 mL 
collection tube and centrifuged (15 s, 14 000 x g, room temperature). The flow-through was 
dropped and this step repeated. Afterwards, 350 µL RW1 buffer was injected on the mini 
column and centrifuged (15 s, 14 000 x g, room temperature). The flow-through was dropped, 
500 µL RPE buffer was added to the column and again centrifuged (15 s, 14 000 g, room 
temperature). Again, the flow-through was dropped and the step was repeated with a longer 
period of centrifugation (2 min, 14000 g, room temperature). The mini column was moved 
onto a new collection tube and centrifuged again to remove residues of buffer from the 
column (1 min, 14000 x g, room temperature). To elute the RNA from the silica-gel 
membrane, 40 µL RNase-free water was injected directly on the silica-gel membrane, 
incubated for 10 min and centrifuged (2 min, 8000 x g). To achieve a higher total RNA 
concentration, this step was repeated. 
For kidney tissue, samples of 30 µg were lysed in a guanidine-isothiocyanate buffer. After 
dilution of the lysate, the sample was treated with proteinase K. Debris was pelleted by 
centrifugation and 600 µL of 70 % v/v ethanol was then added to the cleared lysate. Kidney 
tissue sample preparation was then processed as described for hepatic/intestine tissue, 
skipping the addition of chloroform. The mRNA containing eluates were stored at -70 °C. 
mRNA concentrations in the samples were quantified with a spectrophotometer. The 
extinction of 100 µL of defined diluted eluate was measured at 260 nm and 280 nm. The 
concentration calculated by the extinction at 260 nm (OD260 x 40 = mRNA concentration 
[µg/mL]) was in the range of 3 to 7 µg mRNA/µL with an average of 4.4 ± 1.0 µg/µL. The 
purity of RNA isolation was checked by the ratio OD260nm/OD280nm. The ideal ratio for RNA 
isolation is 2. Lower ratios indicate a contamination with proteins and phenols. A ratio of 1,7 
was accepted but samples with lower ratios were dismissed. 
The integrity of mRNA was checked using an Agilent 2100 bioanalyzer with the RNA6000 
Nano LabChip® reagent set (Agilent Technologies, Santa Clara, USA). This analytical 
method is based on the principal of electrophoresis. 1 µL of diluted sample, containing about 
250 ng RNA were injected into the wells of a RNA nano chip (Eukaryote Total RNA Nano, 
Agilent Technologies, Santa Clara, USA) after a gel-dye mix was transferred into the wells. 
The RNA was separated electrophoretically with long fragments moving slower than small 
fragments. The Agilent 2100 bioanalyzer assigns a RNA integrity number (RIN) based on the 
detected fluorescence signals and allows an estimation of the integrity and degradation of a 
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RNA sample. A RIN of "10" stands for a perfect RNA sample without any degradation 
products, whereas "1" marks a completely degraded sample. The labels in-between are used to 
indicate progressing degradation states of the RNA sample. In our study, samples with a RIN 
of at least 8 were used for further mRNA concentration analyses. 
For determination of relative mRNA concentrations, One-step real-time quantitative RT-PCR 
with SYBR green detection was performed using the iCycler device (BIO-RAD, Munich, 
Germany). All reagents necessary including validated primer sets were purchased from 
Qiagen (Hilden, Germany, Table 6). Reaction parameters were: 30 min at 50 °C (reverse 
transcription), 15 min at 95 °C (hold, 3-step cycling), 15 s at 94 °C (denaturation), 30 s at 55 
°C (annealing), and 30 s at 72 °C (extension, 40 times). All measurements were performed in 
duplicate. PCR data was processed with the iCycler software which specified the threshold 
cycles (CT-values). The CT-value is defined as the fractional PCR cycle number at which the 
reporter fluorescence is greater than the threshold. The ΔΔCT-method was used to calculate 
the relative changes of mRNA concentrations (fold change = FC) of the genes of interest 
(GOI) compared to the housekeeping gene (HKG) according to the following formula (253): 
 
    CT:  threshold cycle;  
    FC:  fold change; 
    E:  efficiency of PCR reaction;  
    GOI:  gene of interest;  
    HKG:  housekeeping gene 
 
 
For controls, the dividend and devisor are the same for each sample, resulting in a ratio = 1 
and consequently no standard deviation occurs. Thus, these values are intended to set a point 
of reference. Genes were considered up- or downregulated if FC was ≥ 1.3 and ≤ 0.7, 
respectively. For all GOI analyzed in liver, 18S-rRNA, which is extensively expressed, was 
used for normalization as HKG. For intestine and kidney, a HKG expressed at low mRNA 
concentrations was necessary to achieve comparability to our GOI. Commonly used reference 
genes with low expression in studies with rats are Alas1, Gusb, Tbp, Tubb4 and Hprt1 of 
which only the latter being expressed in rat intestine. Hprt1 (hypoxanthine-guanine 
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phosphoribosyl-transferase) was used in one study involving OTA-treatment (254) and in 
studies involving quercetin- treatment (255, 256). Therefore, we decided to use Hprt1 as HKG 
in the tissues kidney and intestine. 
 
Table 6:  Specification of primers used for qRT-PCR, provided by Qiagen 
Title of 
gene 
product 
Gene 
symbol 
(rattus 
norvegicus) 
Product name Catalogue 
number 
MRP2 Abcc2 Rn_Abcc2_3_SG QuantiTect Primer Assay QT00365722 
p-gp Abcb1b Rn_Abcb1b_1_SG QuantiTect Primer Assay QT00194719 
BCRP Abcg2 Rn_Abcg2_1_SG QuantiTect Primer Assay QT00183127 
Hprt1 Hprt1 Rn_Hprt1_2_SG QuantiTect Primer Assay QT00365722 
SOD Sod1 Rn_Sod1_1_SG QuantiTect Primer Assay QT00174888 
HO-1 Hmox1 Rn_Hmox1_1_SG QuantiTect Primer Assay QT00175994 
CYP1A1 Cyp1a1 Rn_Cyp1a1_1_SG QuantiTect Primer Assay QT01082018 
CYP1A2 Cyp1a2 Rn_Cyp1a2_2_SG QuantiTect Primer Assay QT01082011 
18sRNA Rn18s Rn_Rnr1_1_SG QuantiTect Primer Assay QT00199374 
 
 
4.7. Statistical analysis 
For statistical analysis of the first experiment data were processed with a three-factorial 
(OTA, quercetin, time) analysis of variance (ANOVA) and Tukey's multiple comparison test  
for the parameter daily OTA-concentrations in urine, using SAS statistical analysis software 
(version 9.2, Institute Inc., Cary, NC, USA) and for all other parameters (feed and water 
consumption, body weight gain, OTA concentrations in tissues and feces) by Student's t-test 
with Graphpad Prism 4 (version 4.01, GraphPad Software, Inc., La Jolla, CA, USA). 
For the second experiment, data of feed consumption and body weight gain were performed 
with a three-factorial (OTA, quercetin, time) ANOVA and Tukey's multiple comparison test 
using SAS. Data of α-TOC and 8-iso-PGF2α analysis were processed with a two-factorial 
(OTA, quercetin) ANOVA and relative mRNA concentrations (FC) with one-factorial 
(treatment) ANOVA and Tukey's multiple comparison test using Graphpad Prism 4 (Version 
4.01, GraphPad Software, Inc., La Jolla, CA, USA). Differences between means were 
considered significant at p < 0.05.  
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5. Results  
5.1. Influence of quercetin on toxicokinetics of OTA 
All animals appeared to be in good health during the course of the first experiment. 
Macroscopic observation at autopsy showed no obvious abnormalities. Table 7 depicts 
average daily feed and water consumption and body weight gain of the animals during the 
experiment.  
 
Table 7:  Average daily feed and water consumption, and body weight gain of rats fed diets containing 
10 mg/kg diet ochratoxin A (OTA) only, and 100 mg/kg diet quercetin (OTA+Q) 
additionally, over an experimental period of 6 days. Values are means ± SD (n = 9).  
 OTA OTA+Q 
Feed consumption (g) 12.7 ± 0.2 12.5  ± 0.4 
OTA consumption (µg) 137.1 ± 2.2 130.0  ± 4.2 
Water consumption (mL) 13.8 ± 1.0 13.3  ± 0.9 
Body weight gain (g) 1.9 ± 0.5 1.7  ± 0.7 
 
Because feed was provided restrictively, daily feed consumption did not differ significantly 
during the 6 days in both feeding groups (Figure 6A). Average daily water consumption 
slightly increased during the experiment in both groups equally from 12 to 14 mL (p < 0.05, 
Figure 6B).  
Figure 6: Daily feed (A) and water (B) consumption of rats fed diets containing 10 mg/kg diet 
ochratoxin A (OTA ●) only, and 100 mg/kg diet quercetin (OTA+Q Δ) additionally, over an 
experimental period of 6 days. Values are means ± SEM (n = 9).  
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Plasma and tissue samples were analyzed for their total OTA concentrations, calculated as the 
sum of OTA and OTα equivalents (Table 8). The highest concentration was measured in 
plasma and in descending order in kidney, liver > muscle > brain. With the exception of blood 
plasma, which contained 0.2 % of total OTA as OTα, no OTα was detected in the other tissues 
investigated. 
 
Table 8:  Total OTA concentrations in plasma and tissues (expressed as sum of OTA and OTA-
equivalents of OTα) of rats fed diets containing 10 mg/kg diet ochratoxin A (OTA) only, and 
100 mg/kg diet quercetin (OTA+Q) additionally, over an experimental period of 6 days. 
Values are means ± SD (n = 9).  
 OTA OTA+Q 
Plasma [µg/mL] 11.27 ± 2.07 10.91 ± 2.38 
Kidney [µg/g] 1.44 ± 0.22 1.42 ± 0.15 
Liver [µg/g] 1.12 ± 0.31 1.94 ± 0.14 
Muscle [µg/g] 0.48 ± 0.09 0.53 ± 0.07 
Brain [µg/g] 0.13 ± 0.02 0.14 ± 0.02 
 
 
Excretion of OTA in urine and feces are shown in Table 9. Daily excretion of OTA and OTα 
via urine increased during the experiment (Figure 7). Total OTA excreted via urine was 
mainly in the form of OTα (93 %) with only a small part (6-7 %) appearing in its 
unmetabolized form. There was no significant difference between the feeding groups. Daily 
excretion of total OTA via feces could not be calculated on an individual base, because fecal 
samples obtained during the experiment were too small. Hence, daily samples were pooled for 
each animal over the experimental period of 6 days. Like in urine, also in feces OTα 
accounted for 94 % of total OTA excreted, the remaining part being excreted as unchanged 
OTA. Again, no significant differences between the groups were obtained. Based on the sum 
of urinary and fecal excretion of total OTA, a retention of the mycotoxin within the body was 
calculated as 70 % of OTA intake. Here, again, no significant differences were found between 
the control and quercetin treated group. 
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Table 9:  Excretion of OTA, OTα (expressed as OTA-equivalents) and total OTA in urine and feces of 
rats fed diets containing 10 mg/kg diet ochratoxin A (OTA □) only, and 100 mg/kg diet 
quercetin (OTA+Q ▲) additionally, after an experimental period of 6 days expressed in 
percent of the consumed amount. Values are means ± SD (n = 9). 
 OTA OTA+Q 
                                                Urine 
OTA 1.1 ± 0.2 1.0 ± 0.1 
OTα 15.7 ± 1.7 14.4 ± 2.4 
Total OTA 16.8 ± 1.8 15.4 ± 2.5 
                                               Feces 
OTA 1.1 ± 0.4 0.9 ± 0.2 
OTα 13.3 ± 1.4 14.0 ± 4.2 
Total OTA 14.2 ± 1.5 15.0 ± 4.4 
Sum of total OTA                       
urine + feces  
30.0 ± 1.5 29.5  ± 5.1
 
 
 
 
 
Figure 7: Daily excretion of OTA (A), OTα 
(B, expressed as OTA-equivalents) and the 
sum of both (C, total OTA) in total urine 
volume of rats fed diets containing             
10 mg/kg diet ochratoxin A (OTA □) only, 
and 100 mg/kg diet quercetin (OTA+Q ▲) 
additionally, depicted as % of daily oral 
OTA-intake over an experimental period of 
6 days. Values are means ± SD (n = 9). 
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5.2. Influence of quercetin and OTA on feed consumption and body weight 
During the second experiment, feed consumption decreased significantly in the groups fed 
OTA (Table 10 and 11). This was already obvious after the first 7 days, where feed intake was 
reduced by about 20 % in both, the OTA and OTA+Q treated groups compared to controls. 
After 21 days, suppression of feed intake was even more pronounced compared to controls at 
the same time (26 and 27 % for OTA and OTA+Q treated group, respectively). At the end of 
the trial (days 22-24), average feed intake was significantly reduced by 8 % in the quercetin 
treated group, by 43% in the OTA treated group, and by 54 % in the OTA+Q treated group, 
compared to controls. 
Like feed consumption, body weight gain of animals fed OTA and OTA+Q was dramatically 
reduced during the trial. Because in the OTA+Q treated group, even body weight loss was 
observed in some animals during the last days, this experiment was terminated ahead of 
schedule. At the end of the trial, the average bodyweight compared to the initial ones were 
+18 %, +17 %, +5 % and +4 % for the groups control, quercetin, OTA and OTA+Q, 
respectively.  
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Table 10: Average feed intake and body weight gain of rats fed a basic diet (control) containing either 10 mg/kg diet ochratoxin A (OTA) or 100 mg/kg diet 
quercetin (Quercetin), or both (OTA+Q) over a period of 24 days. Values are means ± SD (n = 12). Values differ significantly (p < 0.05, ANOVA), if 
small letters differ within a row or capital letters within a column, respectively.   
 Time (days) Control Quercetin OTA OTA+Q  
   
Feed intake (g) 
 
        1- 7 16.5 ± 1.2 
a,A
 16.8 ± 1.1 
a,A
 13.3 ± 0.6 
b,A
 13.2 ± 0.6 
b,A
  
        8-14 15.8 ± 0.4 
a,A
 16.3 ± 0.8 
a,A
 12.7 ± 0.8 
b,A
 12.9 ± 1.1 
b,A
  
      15-21 15.6 ± 1.4 
a,A
 15.8 ± 1.2 
a,A
 11.5 ± 0.6 
b,B
 11.4 ± 1.4 
b,B
  
      22-24 16.5 ± 1.4 
a,B
 15.2 ± 2.0 
b,B
   9.5 ± 1.4 
c,C
   7.6 ± 1.2 
d,C
  
 
Body weight gain (g) 
 
       1- 7 4.1 ± 0.6 
a,A
 4.3 ± 0.8 
a,A
  2.2 ± 0.4 
b,A
  2.3 ± 0.8 
b,A
  
       8-14 3.2 ± 0.4 
a,B
 3.1 ± 0.9 
a,B
  1.0 ± 0.5 
b,B
  0.8 ± 0.8 
b,B
  
     15-21 2.6 ± 0.7 
a,B
 2.6 ± 0.6 
a,C
  0.1 ± 0.7 
b,C
 -0.2 ± 0.7 
b,C
  
     22-24  3.1 ± 0.8 
a,B
 2.1 ± 0.9 
b,B
 -2.3 ± 2.8 
c,D
 -2.5 ± 2.9 
c,D
  
 
 
Table 11: P-values of the factors ochratoxin A (OTA), quercetin, time and their interaction effects, explaining the share of variances for average feed intake and 
body weight gain of rats fed a basic diet, solely or containing either 10 mg/kg diet ochratoxin A (OTA) or 100 mg/kg diet quercetin or both over a 
period of 24 days.  
 OTA quercetin time OTA x quercetin OTA x time Q x time OTA x quercetin x time 
Feed intake < 0.0001 0.6056 < 0.0001 0.3395 < 0.0001 0.3063 0.9446 
Body weight gain < 0.0001 0.2794 < 0.0001 0.8747 < 0.0001 0.4935 0.6017 
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5.3. Influence of quercetin and OTA on oxidative parameters 
To determine possible differences with respect to the oxidative status between the feeding 
groups, concentrations of 8-iso-PGF2α in plasma and α-TOC in plasma, liver, kidney, 
musculus quadriceps and brain were measured.  
Regarding plasma concentrations of 8-iso-PGF2α no significant differences were found 
between the feeding groups (Figure 8).  
 
 
Figure 8: Concentrations of 8-iso-PGF2α  [pg/mL] in blood plasma of rats fed a basic diet (control) 
containing either 10 mg/kg diet ochratoxin A (OTA) or 100 mg/kg diet quercetin (Quercetin), 
or both (OTA+Q) over a period of 24 days. Values are means ± SEM (n = 12), p > 0.5, 
ANOVA. 
 
 
Analysis of α-TOC concentrations in plasma revealed significantly diminished concentrations 
in the groups OTA and OTA+Q down to 55 % and 44 %, respectively, compared to controls 
(Table 12). Because feed intake of animals in these groups OTA and OTA+Q was 
significantly reduced (see above), a regression analysis between the variables “feed intake” 
and “plasma α-TOC concentration” was conducted (Figure 9). Plasma α-TOC concentration 
was highly correlated with feed intake (r
2
 = 0.77, p < 0.0001). 
There were no significant differences in α-TOC concentrations in liver. In kidneys, the α-TOC 
concentrations in the  OTA- and OTA+Q-treated group were significantly elevated by 47 % 
and 65 %, respectively, compared to controls. In muscle, α-TOC concentrations were 
significantly increased in the groups quercetin (+87 %) and OTA (+80 %), whereas it was not 
significant in the OTA+Q-treated group (+51 %), compared to controls. In brain, quercetin 
supplementation lead to a 17 % higher α-TOC concentration compared to controls, which was 
decreased down to 8 % by the combination of OTA with quercetin.  
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Table 12: α-tocopherol concentrations in tissues of rats fed a basic diet (control) containing either 10 mg/kg diet ochratoxin A (OTA) or 100 mg/kg diet 
quercetin (Quercetin), or both (OTA+Q) over a period of 24 days. Values are means ± SD (n = 12). Means are significantly different, if letters differ 
in a row (ANOVA, p < 0.05) and means with two letters are not significantly different to means with the correspondent ones. 
 Treatment
1 
 Effect
2 
  Control Quercetin OTA OTA+Q  OTA quercetin OTA x quercetin 
Plasma  14.4 ± 1.4
a
 13.0 ± 2.5
a
 7.9 ± 3.9
b
 6.3 ± 1.9
b
  < 0.0001    0.0529 0.8372 
Liver  89.7 ± 36.2
a
 86.4 ± 64.7
a
 95.5 ± 57.4
a
 91.1 ± 34.4
a
     0.7909    0.7203 0.9675 
Kidney  80.9 ± 26.4
a
 90.3 ± 19.9
a,b
 118.5 ± 35.3
b,c
 133.2 ± 17.8
c
  < 0.0001    0.1154 0.7279 
Muscle  31.6 ± 13.8
a
 59.0 ± 20.4
b
 56.9 ± 9.6
b
 47.8 ± 24.6
a,b
     0.1840    0.0868 0.0011 
Brain  170.1 ± 9.5
a
 199.3 ± 12.8
b
 175.6 ± 17.1
a
 182.9 ± 17.3
a
     0.2036 < 0.0001 0.0126 
1
 concentrations in  [µg/mL] for plasma and [ng/mg] for the other tissues, respectively. 
2
 p-value   
 
 
Figure 9:Correlation of feed intake and α-TOC concentration in plasma of rats fed a basic diet (control) containing either 10 mg/kg diet ochratoxin A (OTA) or 
100 mg/kg diet quercetin (Quercetin), or both (OTA+Q) over a period of 24 days. Values are means ± SD (n = 12). ● control, ○quercetin, ■ OTA,     
□ OTA+Q; r2, coefficient of determination,  p < 0.0001, regression analysis. 
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To characterize the oxidative status of the animals, relative mRNA concentrations of HO-1 
(gene Hmox1) and Cu
2+
/Zn
2+
-SOD (gene Sod1) were measured in liver and kidney. The 
concentrations of HO-1 mRNA in liver and of SOD mRNA in kidney were below the 
detection limit. However, SOD mRNA was detected in liver and HO-1 in kidney tissue 
(Figure 10). In liver, relative SOD mRNA concentration was significantly higher in all 
treatment groups (FC = 1.3, 1.4 and 1.6 for quercetin, OTA and OTA+Q, respectively) 
compared to the control. In kidney, the relative HO-1 mRNA concentration was significantly 
higher in OTA (FC = 2.4) and OTA+Q (FC = 1.7) compared to controls. A significant 
difference was also found between the groups OTA and OTA+Q (FC = 1.7). Relative HO-1 
mRNA concentrations of  OTA+Q were not significantly different compared to the group 
quercetin (FC = 1.4). 
 
Figure 10: Relative mRNA concentrations depicted as fold change of hepatic SOD (A) and kidney 
HO-1 (B) of rats fed a basic diet (control) containing either 10 mg/kg diet ochratoxin A 
(OTA) or 100 mg/kg diet quercetin (Quercetin), or both (OTA+Q) over a period of 24 
days. Values are means ± SD (n = 5) with 1 ± 0 for control. Significant differences were 
tested with ANOVA, p < 0.5. 
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5.4. Influence of quercetin and OTA on relative mRNA concentrations of 
MRP2, BCRP, P-gp, CYP1A1 and CYP1A2 
The relative mRNA concentrations of the efflux transporters MRP2 (gene Abcc2), BCRP 
(gene Abcg2) and P-gp (gene Abcb1b) were investigated in small intestine (proximal 
jejunum), liver and kidney. Relative mRNA concentrations of the monooxygenases CYP1A1 
(gene Cyp1a1) and CYP1A2 (gene Cyp1a2) were examined in small intestine and liver, only.  
In intestinal tissue, P-gp and CYP1A2 mRNA were not detectable. BCRP, MRP2 and 
CYP1A1 mRNA concentrations were transcribed on a detectable level. Group comparisons 
were conducted and are shown in Figure 11. Compared to controls, relative mRNA 
concentrations of MRP2 and BCRP were significantly higher in the groups OTA+Q             
(FC = 2.2) and OTA/OTA+Q (FC = 1.6 and 1.8), respectively. No significant differences 
between the groups were found for CYP1A1. 
 
 
Figure 11: Relative mRNA concentrations depicted as fold change of MRP2 (A), BCRP (B) and 
CYP1A1 (C) in proximal jejunum of rats fed a basic diet (control) containing either             
10 mg/kg diet ochratoxin A (OTA) or 100 mg/kg diet quercetin (Quercetin), or both 
(OTA+Q) over a period of 24 days. Values are means ± SD (n = 5) with 1 ± 0 for control. 
Significant differences were tested with ANOVA, p < 0.5. 
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In liver samples, CYP1A1, P-gp and BCRP mRNA were not detectable, whereas MRP2 and 
CYP1A2 mRNA were detectable (Figure 12). Relative mRNA concentrations of MRP2 and 
CYP1A2 differed statistically significant in the quercetin-treated group (FC = 1.1) and OTA 
as well as OTA+Q group (FC = 1.1 for both groups), respectively, compared to controls.  
 
 
 
 
Figure 12:  Relative mRNA concentrations depicted as fold change of MRP2 (A) and CYP1A2 (B) in 
liver of rats fed a basic diet (control) containing either 10 mg/kg diet ochratoxin A (OTA) 
or 100 mg/kg diet quercetin (Quercetin), or both (OTA+Q) over a period of 24 days. 
Values are means (n = 5) with 1 ± 0 for control. Significant differences were tested with 
ANOVA, p < 0.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
In kidneys, MRP2 and BCRP mRNA were detectable in all groups (Figure 13). In all three 
treatment groups relative MRP2 mRNA concentrations were significantly decreased 
compared to controls (FC = 0.8, 0.5 and 0.3 for quercetin, OTA and OTA+Q, respectively). 
The relative BCRP mRNA concentration was decreased in OTA+Q treated animals only    
(FC = 0.6), compared to controls. P-gp mRNA was barely expressed at detection level in 
kidney of controls (CT 29.9) and quercetin fed animals (CT 30.4). In the groups OTA and 
OTA+Q CT-values were markedly earlier (CT 25.8 and 24.9, respectively). Hence, relative 
mRNA concentrations of P-gp increased in the groups OTA (FC = 2) and OTA+Q (FC = 1.6), 
compared to the control group. However, results of relative mRNA concentrations of MRP2 
and BCRP should be interpreted carefully, because the HKG Hprt1 also differed with 
treatment to different extent.  
 
Figure 13: Relative mRNA concentrations depicted as fold change of MRP2 (A), P-gp (B) and BCRP 
(C) in kidney of rats fed a basic diet (control) containing either 10 mg/kg diet ochratoxin A 
(OTA) or 100 mg/kg diet quercetin (Quercetin), or both (OTA+Q)  over a period of 24 
days. Values are means (n = 5) with 1 ± 0 for control. Significant differences were tested 
with ANOVA, p < 0.5. 
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6. Discussion 
The aims of our study were to investigate the influence of the plant-derived flavonol quercetin 
on OTA toxicokinetics as well as toxicodynamics. This is based on the facts, that on the one 
hand quercetin may influence mechanisms of OTA metabolism and transport and thus may 
influence OTA toxicokinetics. With respect to the toxicodynamics of OTA, on the other hand, 
pro-oxidative mechanisms are discussed and major biological activities of quercetin are 
thought to be attributable to quercetin’s antioxidative properties. 
In the first experiment, we examined quercetin's influence on OTA toxicokinetics in vivo, 
because it was previously shown, that the co-application of polyphenols and OTA reduced the 
OTA efflux transport across Caco-2 cell membranes and consequently increased the 
intracellular OTA concentration. It was hypothesized, that in vivo competitive inhibition of 
efflux transporter by polyphenols may increase intracellular OTA concentrations in the 
intestinal epithelial cells and thus driving OTA absorption into the blood across the 
basolateral membrane, increasing the systemic bioavailability of OTA (9). It was also 
demonstrated in vitro, that net absorption of OTA into Caco-2 cells was limited due to 
resecretion of OTA via MRP2 and BCRP (37, 45, 88). Hence, changes in the activity of these 
efflux transporters by inhibiting or promoting agents might influence intestinal OTA 
absorption. 
On the one hand polyphenols like quercetin might inhibit OTA resecretion by intestinal 
epithelial cells and in turn might increase systemic availability of OTA. Thus, it was shown 
that quercetin had an inhibitory effect on the activity of BCRP and P-gp in vitro (207, 245, 
246). On the other hand, substances promoting the activity of efflux transporters could reduce 
the systemic availability of OTA by stimulation of resecretion of the mycotoxin. To this 
regard, , quercetin induced the expression of MRP2, BCRP and P-gp. In Caco-2 cells (242, 
247, 257). Obviously, those in vitro studies appears to be contrarious, and only in vivo studies 
are helpful to define the overall effect and its physiological importance. In rats, MRP2, BCRP 
and P-gp are expressed at the apical membrane of intestinal epithelial cells, hepatocytes and 
renal proximal tubulus cells and hence these organs may be primary sites of interaction 
between OTA and quercetin. If quercetin affects either of these OTA-relevant transporters, 
tissue distribution and excretion of OTA and OTα should be affected. In addition, we 
hypothesized that intestinal CYP1A1 and hepatic CYP1A2 detoxify OTA by hydroxylation to 
OH-OTA (63, 64), which is rapidly eliminated, and stimulation of these enzymes by quercetin 
would contribute to a decrease of OTA concentration in plasma and tissues. 
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Results of our first experiment revealed, that about 30 % of the orally fed OTA was excreted. 
The remaining 70 % of OTA were absorbed and distributed into the tissues, primarily kidneys 
and liver, where the highest concentrations of OTA were found aside from plasma. Tissue 
distribution and concentrations of OTA as reported in this work are in good agreement with 
earlier findings (56, 64). Quercetin treatment, however, did not affect concentrations and 
tissue distribution of OTA. In addition, no significant differences in OTA and OTα excretion 
were found between the OTA and OTA+Q treated group. Thus, the hypothesis, that co-
administration of quercetin and OTA may delay OTA excretion due to mutual inhibition of 
both substances could not be substantiated by our findings. The hypothesis, that quercetin 
decreases OTA concentrations in plasma and tissues by stimulating CYPs and thereby 
increasing OTA hydroxylation and elimination, could also not be substantiated by our results. 
Intestinal CYP1A1 and hepatic CYP1A2 relative mRNA concentration analyses revealed no 
detectable expression of CYP1A1 and only a 1.1-fold change of CYP1A2, which is not 
considered as an upregulation. However, regarding OTA toxicokinetics we can not exclude 
that an enhanced expression of cellular exporters like BCRP, MRP2 or P-gp by quercetin, 
which has been shown in cell culture studies (226, 242, 247) could have overcome a 
competitive inhibition between OTA and quercetin or more likely, quercetin conjugates, 
resulting in a zero net effect. To verify this, relative mRNA concentrations of the efflux 
transporters MRP2, BCRP und P-gp after oral uptake of quercetin and OTA were examined in 
our second study. Intestinal BCRP was upregulated 1.6 and 1.8-fold compared to controls in 
the groups OTA and OTA+Q, respectively, pointing to the possibility that OTA might be 
resecreted across the apical membrane mainly by BCRP. Only when quercetin was co-applied 
with OTA, intestinal MRP2 was upregulated 2.2-fold (OTA+Q), compared to controls. These 
finding could be explained with an adaptation of apical transport capacity to the higher 
substrate availability, thus compensating competitive inhibition between both substrates. 
Probably, the transport capacity of the MRP2 in the apical membranes of intestinal epithelial 
cells was sufficient when either one of the substrates quercetin or OTA were fed solely, 
because no increase of MRP2 mRNA concentration was observed in the respective feeding 
groups   
Regarding the efflux transporters in other tissues, our results revealed, that in liver, P-gp and 
BCRP were not detectable and MRP2 was not regulated by OTA or quercetin. 
In contrast,  MRP2 was downregulated 0.5-fold in response to OTA in kidney. On the one 
hand, downregulation of this transporter might lead to accumulation of OTA in proximal 
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tubulus cells resulting in adverse pro-oxidative effects as elucidated below; on the other hand, 
P-gp expression was induced in response to OTA, implicating again a compensatory 
mechanism for the diminished MRP2 transport capacity. Downregulation of MRP2 and 
upregulation of P-gp at the same time after OTA-administration in rats was also observed by 
Marin-Kuan et al. (138) in a recently conducted study investigating the mRNA concentration 
profiles in response to OTA in F344 rat kidneys under similar conditions as we used            
(0.3 mg/kg b.w., 21 days). The OTA induced upregulation of P-gp might implicate an OTA 
transport by P-gp in renal proximal tubulus cells. To date, OTA transport mediated by P-gp 
was only studied in Caco-2 cells, where it was not a substrate for P-gp (45). But it has to be  
noticed, that in contrast to in vivo, cultured cells sometimes show declines in special transport 
capacities (258). However, the supplementation of quercetin, which itself did not influence 
MRP2, BCRP or P-gp expression significantly, downregulated MRP2 in addition to the OTA-
effect. Furthermore, only in this treatment group (OTA+Q) renal BCRP was downregulated 
0.6-fold and the induction of P-gp was decreased from 2 to 1.6-fold compared to OTA fed 
solely. This could be partly explained by the reported inhibiting action of quercetin on P-gp 
expression (234, 236). However, as mentioned in chapter 5.4. results and interpretation of 
renal MRP2 and BCRP expression must be regarded carefully. 
Taken together, whereas in vitro, a competitive inhibition between OTA and quercetin with 
respect to resecretion resulting in intracellular accumulation of OTA was observed (9), in vivo 
results indicate adaptive mechanisms concerning the expression and or activity of the 
involved transporters on a molecular level. In a comparative study addressing the mRNA 
concentration profiles from renal cell cultures and rat proximal tubulus cells in response to 
OTA, especially proteins involved in biotransformation processes were regulated in vivo, but 
not in vitro (141). These contradictory results could be explained by the fact that cell cultures, 
as usually used in studies, lack the whole complexity of hormonal and immunological 
influences as present in the intact organism (141).  
 
In our second trial, the influence of quercetin on OTA toxicodynamics was examined. The 
daily consumption of a chronically toxic OTA dose with the feed clearly reduced feed intake 
and body weight gain in OTA-treated animals as observed in another study (259). Quercetin, 
which itself did not substantially influence feed consumption and body weight gain added to 
the OTA-containing feed, however, did not amend the adverse effects of OTA. The toxic 
effects were hypothesized to be the consequence of OTA-derived oxidative stress. 
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In order to assess the oxidative status of the experimental animals, we measured 8-iso-PGF2α
 
in plasma and α-TOC concentrations in plasma and tissue samples of liver, kidney, musculus 
quadriceps, and brain as well as relative mRNA concentrations of HO-1 and Cu
2+
/Zn
2+
-SOD 
in liver and kidney. Because 8-iso-PGF2α
 
concentrations in blood plasma did not differ 
between the feeding groups, no evidence was obtained for an increased lipid peroxidation in 
the OTA-treated animals. Comparable findings were made by Gaultier et al. (259), who did 
not find evidence for lipid peroxidation determined as MDA concentrations in rat's plasma 
after an exposure to OTA (2 g/kg b.w., 24 h). In addition to 8-iso-PGF2α we measured the α-
TOC concentration. Alpha-TOC functions as a chain-breaking antioxidant that prevents the 
propagation of free radical reactions; hence, a decrease of α-TOC in tissues usually implicates 
a shift in oxidative balance to oxidative stress (260). In our trial, plasma α-TOC 
concentrations in both OTA-treated groups were significantly decreased compared to control 
and the quercetin-treated group. On a first glance, this could be interpreted as an increased 
oxidative stress caused by OTA leading to an enhanced consumption of α-TOC. More likely, 
however, this finding can be explained by the reduced feed consumption in the OTA-treated 
animals as a result of OTA-related toxicity, rather than an enhanced oxidative stress caused by 
the mycotoxin. In addition, quercetin again did not prevent the OTA effect on plasma α-TOC 
concentration. 
In kidneys significantly higher α-TOC concentrations were recorded in those animals solely 
treated with quercetin or with OTA. Whereas the increased α-TOC concentrations in the 
quercetin-fed group may indicate an vitamin E-sparing effect (168), the increased α-TOC 
concentrations in response to OTA are in contrast to results published by Gautier et al. (259), 
who found a 22 % decrease of α-TOC in the kidney after OTA exposure. These equivocal 
results may be attributable to different duration of the trials (24 d vs. 24 h). Possibly, in our 
trial time was given for a redistribution of α-TOC to tissues with higher need for vitamin E in 
response to OTA. This could be triggered by a receptor mediated uptake of α-TOC, like the 
phospholipid transfer protein or the scavenger-receptor BI, which were involved in α-TOC 
uptake into extrahepatic tissues (261, 262). In fact, in a study with rats examining the 
relationship between hydrazine-induced oxidative stress and α-TOC concentrations in tissues, 
it was reported, that in those tissues in which a significant increase of oxidative stress was 
measurable, also the α-TOC concentrations were significantly increased and plasma 
concentrations decreased (263). Based on a positive correlation between tissue α-TOC 
concentration and local oxidative stress, our result of kidney α-TOC concentration could even 
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be interpreted as an evidence for pro-oxidative OTA-effects in this organ. This would make 
sense regarding our results of mRNA analyses. As an early indicator of a cellular answer to 
oxidative stress, relative mRNA concentrations of HO-1 as well as Cu
2+
/Zn
2+ 
SOD were 
determined in liver and kidney. HO-1, an enzyme of heme catabolism, cleaves heme to form 
biliverdin. It responds immediately to changes in cellular redox potential caused by multiple 
agents like ROS generating systems, xenobiotics or changes in oxygen tension (144). The 
cytosolic Cu
2+
/Zn
2+
-dependent SOD protects cells from ROS by catalyzing the 
disproportionation of superoxide anion radicals into molecular oxygen and hydrogen peroxide 
(264). Hence, in the case of oxidative stress, HO-1 and Cu
2+
/Zn
2+ 
SOD expression could be 
expected to be increased. The gene expression analyses of our data revealed an 2.4-fold 
upregulation of HO-1 in kidneys of OTA-fed animals, which indeed could indicate oxidative 
stress. This is in accordance with the studies by Marin-Kuan et al. (138) and Gautier et al. 
(259), where elevated HO-1 expressions in rat kidneys were found after OTA exposure. 
Concerning expression data of the renal efflux transporters in the present study (see above), 
the downregulation of MRP2 might have contributed to OTA accumulation in renal proximal 
tubulus cells resulting in pro-oxidative effects and in turn stimulating HO-1 expression. 
Although P-gp was induced in parallel, this could not (fully) compensate for the decreased 
transport capacity due to the reduced activity of MRP2. Co-administration of quercetin and 
OTA decreased the upregulation of HO-1 from 2.4 fold (OTA) to 1.7 fold (OTA+Q). This 
could be interpreted, that quercetin only partially reduced OTA-derived oxidative stress. 
Because quercetin appearingly downregulated all three efflux transporters (MRP2, BCRP, and 
P-gp) in the kidney, a reduction of oxidative stress by quercetin due to higher OTA secretion 
was probably not the underlaying mechanism. In addition, because Cu
2+
/Zn
2+ 
SOD was not 
detectable in kidneys of all experimental animals, this enzyme most likely did not contribute 
to the reduction of oxidative stress. Hence, other quercetin-derived mechanism not directly 
addressed in this study must be considered. Nevertheless, our results obtained from the in vivo 
investigations confirms a very recently conducted in vitro study, in which quercetin 
ameliorated OTA-induced oxidative stress in vero monkey kidney cells by activation of the 
Nrf2 transcription factor (265). 
In liver, α-TOC concentrations were not significantly different between all feeding groups and 
HO-1 was not expressed on a detectable level in this tissue, but Cu
2+
/Zn
2+ 
SOD was 
upregulated in response to quercetin (1.3-fold), OTA (1.4-fold) and the combination of both 
(1.6-fold). These results are in accordance with studies of Gautier et al. (259) and Marin-Kuan 
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et al. (138). Those authors did not find altered α-TOC concentrations in liver (259) and 
although HO-1 was detected in the livers of rats in those studies it was not reported to be 
upregulated (138, 259). Hence, no evidence was obtained for a pro-oxidative effect of OTA in 
liver. Because of the elevated relative mRNA concentrations of Cu
2+
/Zn
2+ 
SOD in both OTA-
fed groups, it could be possible in our study, that the upregulation of this antioxidative 
enzyme prevented the manifestation of OTA-induced oxidative stress. Quercetin itself 
increased relative Cu
2+
/Zn
2+ 
SOD mRNA concentrations (1.3-fold) like reported before (266) 
confirming the stimulation of endogenous antioxidative systems. The stimulating effects of 
quercetin on Cu
2+
/Zn
2+ 
SOD expression combined with the OTA-induced effects on this 
enzyme might interact synergistically, resulting in a stronger upregulation of Cu
2+
/Zn
2+ 
SOD 
when OTA and quercetin were co-applicated. 
Taken together, we hypothesized that quercetin would decrease OTA-induced pro-oxidative 
effects. Our results show that OTA indeed induced oxidative stress in the kidney, as measured 
by increased α-TOC concentrations (redistribution of vitamin E due to higher need) and 
relative HO-1 mRNA concentrations. Quercetin was able to decrease relative HO-1 mRNA 
concentrations and thus may act as an antioxidant. In liver, no evidence for oxidative stress 
was obtained, but probably defence mechanism like the Cu
2+
/Zn
2+ 
SOD prevented the 
manifestation of oxidative stress. Our  findings further implicate, that after 24 days of trial, 
induction of oxidative stress by OTA in F344 rats was at an early stage. Clearly, toxic effects 
of the chronically fed dose of OTA used in our study were feasible when body weight gain of 
the experimental animals decreased. At an early stage of OTA intoxication, the kidney is the 
first organ to be affected (100) and HO-1 is an early indicator for oxidative stress (144). The 
liver is only affected after long-term and severe intoxication (104). 
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7. Summary 
Subject of this work was to examine if dietary applicated quercetin influences OTA 
toxicokinetics and toxicity in growing male F344 rats. We stated the hypothesis, that co-
administration of quercetin and OTA may increase delay of OTA excretion due to a 
competitive inhibition of both substances during elimination. In addition, we hypothesized, 
that the potent antioxidant quercetin diminishes OTA derived oxidative stress. Therefore, two 
experiments were conducted. 
In the first one, the two experimental groups (n = 9) received OTA added to the feed             
(10 mg/kg diet, daily intake of 0.6 mg/kg b.w.) of which one was supplemented with quercetin 
(100 mg/kg diet), additionally. OTA and the main metabolite OTα were measured in daily 
collected urine and feces, and in plasma, kidney, liver, brain and musculus quadriceps. Our 
results revealed, that 30 % of the totally consumed OTA was excreted with feces and urine 
mainly in the form of OTα. In the tissues, highest OTA-concentrations were found in plasma 
and in descending order in kidney/liver, muscle and brain. No significant differences were 
found between the animals who received OTA only, or OTA and quercetin. 
In the second experiment four groups (n = 12) received the basic diet (Control), supplemented 
with either 100 mg/kg quercetin (Quercetin) or 10 mg/kg OTA (OTA) or both. Feed 
consumption and body weight gain were measured. Animals receiving OTA suffered from 
reduced body weight gain due to reduced feed intake. Additional supplementation of 
quercetin did not improve this findings. Oxidative parameters were measured in plasma and in 
tissues. Our results on 8-iso-PGF2α, α-TOC and relative mRNA concentrations of HO-1 and 
SOD indicate that OTA induced oxidative stress in the kidney and quercetin was able to 
decrease relative HO-1 mRNA concentrations, but not any other parameter for oxidative 
stress we measured. In liver, no evidence for oxidative stress was obtained, but probably 
defence mechanism like Cu
2+
/Zn
2+ 
SOD prevented the manifestation of OTA-induced 
oxidative stress. Our results on relative mRNA concentration analysis of the efflux transporter 
indicated an apical OTA transport mediated by intestinal BCRP and when OTA and quercetin 
were co-administered by MRP2. Also, renal P-gp was induced by OTA implicating P-gp 
mediated OTA secretion in the kidney. 
We concluded, that in respect of OTA toxicokinetics in vivo the competitive inhibition of 
intestinal resecretion and renal tubular secretion by quercetin and OTA, as shown in vitro, was 
overcome by the upregulation of intestinal and renal efflux transporters and that quercetin was 
able to diminish OTA-induced pro-oxidative effects on molecular level. 
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8. Zusammenfassung 
Ziel dieser Arbeit war es zu untersuchen, ob im Futter verabreichtes Quercetin die Ochratoxin 
A (OTA)-Toxikokinetik und Toxizität bei adulten männlichen F344 Ratten beeinflusst. Es 
sollte einerseits geklärt werden, ob Quercetin zu einer Verzögerung der OTA Exkretion 
aufgrund von kompetitiver Hemmung während der Elimination kommt. Andererseits sollte 
untersucht werden, ob das Antioxidans Quercetin den pro-oxidativen Effekten von OTA 
entgegenwirken kann. Es wurden zwei Versuche durchgeführt, in denen eine Basisdiät ohne 
oder mit Supplementierung von OTA (10 mg/kg Diät, tägliche Aufnahme von 0.6 mg/kg 
Körpergewicht) und/oder Quercetin (100 mg/kg Diät) verfüttert wurde ("Kontrolle", "OTA", 
"OTA+Q", bzw. "Quercetin"). Im ersten Versuch wurde die Toxikokinetik von OTA in den 
Gruppen OTA und OTA+Q (n = 9) untersucht. 30 % der insgesamt aufgenommenen OTA-
Menge wurde mit dem Urin und dem Kot ausgeschieden, hauptsächlich in Form des 
Hauptmetaboliten OTα. In den Geweben wurde die höchste Konzentration im Plasma und in 
absteigender Reihenfolge in der Niere/Leber, Muskel und im Hirn gefunden. Es wurden keine 
signifikanten Unterschiede zwischen den Gruppen gefunden. Im zweiten Experiment wurden 
alle vier Versuchsgruppen (n = 12), Kontrolle, Quercetin, OTA und OTA+Q, miteinander 
verglichen. Tiere die OTA bekamen hatten eine reduzierte Gewichtszunahme aufgrund 
reduzierter Futteraufnahme. Eine zusätzliche Supplementierung von Quercetin änderte diesen 
Befund nicht. Die Ergebnisse der Gewebeanalysen oxidativer Prameter, 8-iso-PGF2α, α-TOC 
und relativer mRNA Konzentration von HO-1 und SOD, zeigten, dass OTA das frühe 
Indikatorgen für oxidativen Stress HO-1 in der Niere hochregulierte und dies gemeinsam mit 
einer erhöhten α-TOC Gewebekonzentration auf pro-oxidative Effekte schließen lässt. Die 
Zugabe von Quercetin verminderte die HO-1 Expression. In der Leber wurde kein Hinweis 
für oxidativen Stress gefunden. Möglicherweise verhinderten die durch OTA und Quercetin 
stimulierten zelleigenen antioxidativen Abwehrmechanismen wie SOD die Manifestation von 
oxidativem Stress. Die mRNA-Konzentrationsanalysen der Effluxtransporter weisen darauf 
hin, dass die Hochregulation der intestinalen Transporter BCRP und MRP2 und des renalen P-
gp eine kompetetive Hemmung, wie sie in vitro demonstriert wurde, kompensierten.  
Aus den Ergebnissen kann geschlossen werden, dass Quercetin die Toxikokinetik von OTA 
nicht beeinflusst, weil in vivo eine Hochregulation von Effluxtransportern eine kompetitive 
Hemmung der intestinalen sowie der renalen tubulären Sekretion kompensierte und dass 
Quercetin in der Niere in der Lage war, von OTA verursachte prooxidative Effekte auf 
molekularer Ebene zu vermindern. 
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